<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">20068</article-id><article-id pub-id-type="doi">10.7554/eLife.20068</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Genes and Chromosomes</subject></subj-group></article-categories><title-group><article-title>Methylated <italic>cis</italic>-regulatory elements mediate KLF4-dependent gene transactivation and cell migration</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-66920"><name><surname>Wan</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa1">†</xref></contrib><contrib contrib-type="author" id="author-66921"><name><surname>Su</surname><given-names>Yijing</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-4487"><name><surname>Song</surname><given-names>Qifeng</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-66922"><name><surname>Tung</surname><given-names>Brian</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-84965"><name><surname>Oyinlade</surname><given-names>Olutobi</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8932-2764</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-84966"><name><surname>Liu</surname><given-names>Sheng</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-66923"><name><surname>Ying</surname><given-names>Mingyao</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-4494"><name><surname>Ming</surname><given-names>Guo-li</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-4496"><name><surname>Song</surname><given-names>Hongjun</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-4485"><name><surname>Qian</surname><given-names>Jiang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-21028"><name><surname>Zhu</surname><given-names>Heng</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-4493"><name><surname>Xia</surname><given-names>Shuli</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5849-6967</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor3">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">The Wilmer Eye Institute</institution>, <institution>Johns Hopkins University School of Medicine</institution>, <addr-line><named-content content-type="city">Baltimore</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Department of Neurology</institution>, <institution>Johns Hopkins University School of Medicine</institution>, <addr-line><named-content content-type="city">Baltimore</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Institute for Cell Engineering</institution>, <institution>Johns Hopkins University School of Medicine</institution>, <addr-line><named-content content-type="city">Baltimore</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Department of Pharmacology and Molecular Sciences</institution>, <institution>Johns Hopkins University School of Medicine</institution>, <addr-line><named-content content-type="city">Baltimore</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><label>5</label><institution content-type="dept">Center for High-Throughput Biology</institution>, <institution>Johns Hopkins University School of Medicine</institution>, <addr-line><named-content content-type="city">Baltimore</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><label>6</label><institution>Hugo W Moser Research Institute at Kennedy Krieger</institution>, <addr-line><named-content content-type="city">Baltimore</named-content></addr-line>, <country>United States</country></aff><aff id="aff7"><label>7</label><institution content-type="dept">The Solomon Snyder Department of Neuroscience</institution>, <institution>Johns Hopkins University School of Medicine</institution>, <addr-line><named-content content-type="city">Baltimore</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ren</surname><given-names>Bing</given-names></name><role>Reviewing editor</role><aff><institution>University of California, San Diego School of Medicine</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><email>jiang.qian@jhmi.edu</email> (JQ);</corresp><corresp id="cor2"><email>hzhu4@jhmi.edu</email> (HZ);</corresp><corresp id="cor3"><email>xia@kennedykrieger.org</email> (SX)</corresp><fn fn-type="present-address" id="pa1"><label>†</label><p>Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, United States</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>29</day><month>05</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>6</volume><elocation-id>e20068</elocation-id><history><date date-type="received"><day>20</day><month>08</month><year>2016</year></date><date date-type="accepted"><day>24</day><month>05</month><year>2017</year></date></history><permissions><copyright-statement>© 2017, Wan et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Wan et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-20068-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.20068.001</object-id><p>Altered DNA methylation status is associated with human diseases and cancer; however, the underlying molecular mechanisms remain elusive. We previously identified many human transcription factors, including Krüppel-like factor 4 (KLF4), as sequence-specific DNA methylation readers that preferentially recognize methylated CpG (mCpG), here we report the biological function of mCpG-dependent gene regulation by KLF4 in glioblastoma cells. We show that KLF4 promotes cell adhesion, migration, and morphological changes, all of which are abolished by R458A mutation. Surprisingly, 116 genes are directly activated via mCpG-dependent KLF4 binding activity. In-depth mechanistic studies reveal that recruitment of KLF4 to the methylated <italic>cis</italic>-regulatory elements of these genes result in chromatin remodeling and transcription activation. Our study demonstrates a new paradigm of DNA methylation-mediated gene activation and chromatin remodeling, and provides a general framework to dissect the biological functions of DNA methylation readers and effectors.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20068.001">http://dx.doi.org/10.7554/eLife.20068.001</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author Keywords</title><kwd>DNA methylation</kwd><kwd>histone modification</kwd><kwd>cell migration</kwd><kwd>KLF4</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research Organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01NS091165</award-id><principal-award-recipient><name><surname>Xia</surname><given-names>Shuli</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>EY024580</award-id><principal-award-recipient><name><surname>Qian</surname><given-names>Jiang</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 GM111514</award-id><principal-award-recipient><name><surname>Zhu</surname><given-names>Heng</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.5</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A new paradigm of DNA methylation mediated gene activation and chromatin remodeling provides a general framework to dissect the biological functions of DNA methylation readers and effectors.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>DNA methylation at the five position of the cytosine base (5mC) is the primary epigenetic modification on the mammalian genomic DNA (<xref ref-type="bibr" rid="bib25">Jaenisch and Bird, 2003</xref>), and dysregulation of DNA methylation is a hallmark of various diseases and cancer (<xref ref-type="bibr" rid="bib41">Sharma et al., 2010</xref>). CpG methylation in <italic>cis</italic>-regulatory elements is generally believed to repress gene expression by disrupting transcription factor (TF)-DNA interactions directly or indirectly via the recruitment of proteins containing methyl-CpG-binding domain (MBD), which are largely sequence independent (<xref ref-type="bibr" rid="bib3">Boyes and Bird, 1991</xref>). This dogma has been challenged by several recent studies in which many TFs were identified as a new class of sequence-specific methylated DNA readers (<xref ref-type="bibr" rid="bib16">Filion et al., 2006</xref>; <xref ref-type="bibr" rid="bib32">Mann et al., 2013</xref>; <xref ref-type="bibr" rid="bib37">Rishi et al., 2010</xref>; <xref ref-type="bibr" rid="bib39">Sasai et al., 2010</xref>; <xref ref-type="bibr" rid="bib40">Serra et al., 2014</xref>; <xref ref-type="bibr" rid="bib42">Spruijt et al., 2013</xref>; <xref ref-type="bibr" rid="bib51">Zhu et al., 2016</xref>). For example, a large-scale survey against the human TF repertoire revealed that 47 TFs and co-factors, including the Krüppel-like factor 4 (KLF4), recognize mCpG-containing DNA motifs in a sequence-specific manner (<xref ref-type="bibr" rid="bib23">Hu et al., 2013</xref>). In addition to its canonical DNA motif, KLF4 also recognizes a different motif that requires CpG methylation (i.e., 5’-CmCGC). Further mutagenesis studies demonstrated that Arg458-to-Alanine (R458A) mutation in KLF4 abolished its interaction with the methylated DNA motif, but showed no detectable impact on binding to its canonical, unmethylated motifs (<xref ref-type="bibr" rid="bib23">Hu et al., 2013</xref>). Intriguingly, cell-based luciferase assays showed that KLF4 wild type (WT) could recognize methylated promoter and activate downstream transcription; while R458A mutant could not (<xref ref-type="bibr" rid="bib23">Hu et al., 2013</xref>). The crystal structure of KLF4 binding to mCpGs was published by an independent study (<xref ref-type="bibr" rid="bib30">Liu et al., 2014</xref>). However, the physiological function of the mCpG-dependent KLF4 binding activity in mammalian cells remains unknown.</p><p>KLF4 plays multiple roles in normal physiology and disease. It is one of the Yamanaka factors that induce pluripotency in somatic cells (<xref ref-type="bibr" rid="bib33">Nandan and Yang, 2009</xref>). KLF4 also functions as a cancer driver gene (<xref ref-type="bibr" rid="bib45">Vogelstein et al., 2013</xref>), and is involved in cancer stem cell maintenance (<xref ref-type="bibr" rid="bib28">Leng et al., 2013</xref>; <xref ref-type="bibr" rid="bib50">Yu et al., 2011</xref>; <xref ref-type="bibr" rid="bib52">Zhu et al., 2014</xref>). For example, Our previous studies indicate that treatment of cancer cells with hepatocyte growth factor induced cancer stem cell phenotypes by increasing the expression of reprograming factors including KLF4 (<xref ref-type="bibr" rid="bib29">Li et al., 2011</xref>). KLF4 has also been shown to be upregulated in high-grade brain tumors (<xref ref-type="bibr" rid="bib11">Elsir et al., 2014</xref>; <xref ref-type="bibr" rid="bib21">Holmberg et al., 2011</xref>), such as glioblastoma (GBM), the most aggressive and lethal adult brain tumor (<xref ref-type="bibr" rid="bib5">Carlsson et al., 2014</xref>; <xref ref-type="bibr" rid="bib35">Quick et al., 2010</xref>). In addition to driving tumor malignancy, KLF4 can act as a tumor suppressor in distinct cellular contexts (<xref ref-type="bibr" rid="bib12">Evans and Liu, 2008</xref>; <xref ref-type="bibr" rid="bib38">Rowland et al., 2005</xref>; <xref ref-type="bibr" rid="bib44">Tetreault et al., 2013</xref>).</p><p>In this study, we dissected the biological function of KLF4 binding to methylated DNA in malignant brain tumor cells by taking advantage of the R458A mutant lacking the ability to bind to methylated DNA. Our study showed that KLF4-mCpG interaction promotes brain tumor cell migration via the transactivation of genes involved in cell motility pathways, including the small GTPase <italic>RHOC</italic>. We further demonstrate that recruitment of KLF4 to methylated <italic>cis</italic>-regulatory elements results in chromatin remodeling and activation of gene transcription in a genome-wide scale.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>KLF4-mCpG interaction promotes GBM cell adhesion and migration</title><p>We chose two human GBM cell lines, namely U87 and U373, with physiologically relevant genetic backgrounds to dissect the function of mCpG-dependent KLF4 binding activity, and because these two cell lines have low endogenous KLF4 expression. To facilitate in vivo studies of mCpG-dependent binding activity of KLF4, we engineered two stable cell lines that, upon doxycycline (Dox) treatment, each expressed KLF4 WT or KLF4 R458A. Cells without doxycycline treatment served as a negative control. Western blot analysis and immunocytochemistry staining confirmed that the endogenous KLF4 level in non-transfected U87 cells was barely detectable; after 48 hr Dox induction, both KLF4 WT and R458A proteins showed a dose-dependent increase without an impact on cell proliferation (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A,B</xref>). For the rest of the study, we chose the Dox dose 1 µg/ml, which induced KLF4 expression to a level (~20–27 fold) similar to that during cancer cell reprogramming when challenged by growth factors (<xref ref-type="bibr" rid="bib29">Li et al., 2011</xref>).<fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.20068.002</object-id><label>Figure 1.</label><caption><title>Methyl CpG-dependent KLF4 binding activity promoted GBM cell adhesion and migration.</title><p>(<bold>A</bold>) Induced expression of KLF4 WT and R458A in human U87 GBM cells upon doxycycline (Dox) treatment. Cells were transfected with lentivirus harboring tet-on KLF4 WT or R458A constructs and selected with antibiotics. Stable cell lines were treated with Dox for 48 hr before immunoblotting. Immunoblotting showing induced expression of KLF4 WT and R458A in human U87 GBM cells upon doxycycline (Dox) treatment. (<bold>B and C</bold>) KLF4 WT but not R458A promoted GBM cell adhesion. Cells were pre-treated with Dox for 48 hr and plated for 2 hr before washing. (<bold>D and E</bold>) KLF4 WT promoted GBM cell migration in broyden chamber transwells. Cells were pretreated with Dox for 48 hr, plated on transwells containing 0.1% FCS and migrating towards 10% FCS. After 3 hr, migrating cells were stained with DAPI and five field / transwell were counted. (<bold>F</bold>) KLF4 WT but not R458A promoted GBM cell migration in wound healing assays. Cells were treated with Dox for 5 days till confluence. A scratch was made and cells were maintained in 0.1% FCS medium overnight, cell proliferation was inhibited by mitomycin C. Microphotographs were taken 0 hr and 24 hr after scratching. Bar = 25 µm. ***p&lt;0.001.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20068.002">http://dx.doi.org/10.7554/eLife.20068.002</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20068-fig1-v2"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.20068.003</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Expression of KLF4 WT and R458A mutant did not affect cell growth.</title><p>(<bold>A</bold>) Immunocytochemistry staining of KLF4 cellular location. Human U87 GBM cells express low level of endogenous KLF4 protein, which was evenly spread in cytoplasma and nucleus. Dox induction of KLF4 WT and R458A expression resulted in strong KLF4 staining in the nucleus. Bar = 10 µm. (<bold>B</bold>) KLF4 WT and R458A had no effect on cell growth 5 days post Dox (1 µg/ml) treatment as determined by trypan blue staining. (<bold>C</bold>) Scratch assays for 48 hr in KLF4 WT expressing cells (+Dox) in comparison with non-transfected U87 parent cells and KLF4 R458A expressing cells. Bar = 25 µm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20068.003">http://dx.doi.org/10.7554/eLife.20068.003</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20068-fig1-figsupp1-v2"/></fig></fig-group></p><p>We observed that induction of KLF4 WT significantly increased cell adhesion (<xref ref-type="fig" rid="fig1">Figure 1B,C</xref>) and promoted migration in both transwell assays and wound healing assays (<xref ref-type="fig" rid="fig1">Figure 1D–F</xref>). Similar results were obtained at 24- and 48 hr post induction (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). In contrast, induction of R458A had no detectable impact on either cell adhesion or migration (<xref ref-type="fig" rid="fig1">Figure 1B–F</xref>). Consistent with the observed phenotypes, KLF4 WT-expressing cells showed elongated, spindle-like morphology (arrows, <xref ref-type="fig" rid="fig2">Figure 2A</xref>), whereas control and R458A-expressing cells remained round and small (arrowheads, <xref ref-type="fig" rid="fig2">Figure 2A</xref>). Quantitative analysis further confirmed this observation (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Immunofluorescence staining for F-actin and vinculin further confirmed the formation of stress actin fibers and focal adhesion, respectively, in KLF4 WT-expressing GBM cells (arrowheads), but not in R458A-expressing cells (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Similar results were observed in other GBM cell lines, such as U373 GBM cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–D</xref>). Since R458A loses binding activity to mCpG-containing motifs but retains binding to unmethylated canonical motifs (<xref ref-type="bibr" rid="bib23">Hu et al., 2013</xref>), these phenotypic differences can be attributed to the mCpG-dependent KLF4 activity.<fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.20068.004</object-id><label>Figure 2.</label><caption><title>KLF4 WT-induced cell migration is methylation dependent.</title><p>(<bold>A</bold>) Expression of KLF4 WT but not R458A induced cell morphology changes in U87 cells (+Dox, 48 hr). The control and R458A expressing cells showed round and short cell body (arrowheads), whereas KLF4 WT induced elongated, spindle-like cell shape (arrows). Bar = 25 µm. (<bold>B</bold>) Quantification of cell morphology changes after Dox treatment for 48 hr. More than 80% of the KLF4 WT expressing cells showed elongated, spindle-like cell morphology, whereas most KLF4 R458A expressing cells remained as round and short cells. (<bold>C</bold>) F-actin and vinculin staining in control, KLF4 WT and R458A-expressing cells. KLF4 WT induced actin stress fiber formation and focal adhesion formation (arrowheads). Bar = 10 µm. (<bold>D</bold>) Pre-treatment of the cells with DNA methyltransferase inhibitor 5-Aza (1µmol/L, 10 days) blocked KLF4 WT-induced cell migration in transwell assays. (<bold>E</bold>) Scratch assays indicating that 5-Aza blocked wound healing induced by KLF4 WT. Bar = 25 µm. ***p&lt;0.001.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20068.004">http://dx.doi.org/10.7554/eLife.20068.004</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20068-fig2-v2"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.20068.005</object-id><label>Figure 2—figure supplement 1.</label><caption><title>Methyl CpG-dependent KLF4 binding activity promoted adhesion and migration of human U373 GBM cells.</title><p>(<bold>A and B</bold>) mCpG-dependent KLF4 binding promoted U373 cell migration in wound healing assays. Cell migration distance was plotted in (<bold>B</bold>). Bar = 25 µm. (<bold>C</bold>) KLF4 WT but not R458A promoted U373 GBM cell migration in transwell assays. (<bold>D</bold>) KLF4-WT but not R458A promoted adhesion of U373 GBM cells, as measured by MTT assays (***p&lt;0.001).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20068.005">http://dx.doi.org/10.7554/eLife.20068.005</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20068-fig2-figsupp1-v2"/></fig></fig-group></p><p>To confirm that the observed phenotypes were DNA methylation dependent, we pre-treated the cells with a DNA methytransferase inhibitor, 5-aza-2′-deoxycytidine (5-Aza, 1µmol/L), which eliminates DNA methylation on a genome-wide scale (<xref ref-type="bibr" rid="bib7">Chen et al., 1998</xref>). As illustrated in <xref ref-type="fig" rid="fig2">Figures 2D,E</xref>, 5-Aza treatment partially suppressed the enhanced cell migration and wound healing phenotypes driven by KLF4 WT, suggesting that the increased cell migration was indeed mediated via a DNA methylation-dependent mechanism.</p></sec><sec id="s2-2"><title>Identification of transcriptional network regulated by KLF4-mCpG interactions</title><p>The distinct phenotypes induced specifically by KLF4 WT suggested that mCpG-dependent KLF4 binding events regulate the expression of genes involved in these biological processes. To elucidate the molecular mechanisms by which KLF4 regulates gene transcription via its mCpG-dependent activity, we carried out a series of genome-wide analyses to identify the direct gene targets that are regulated by KLF4 WT but not R458A.</p><p>First, we performed RNA-seq analysis before (0 hr) and after (48 hr) induction of KLF4 WT and R458A, respectively. Approximately 86% of the sequencing reads were uniquely mapped to the human genome (<xref ref-type="supplementary-material" rid="SD1-data">Figure 3—source data 1</xref>); comparison of the expression profiles between the replicates showed high reproducibility (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). Differentially expressed genes (DEGs) after KLF4 induction were identified by comparing gene expression at 48 hr versus 0 hr of KLF4 expression. We observed that a total of 613 genes were significantly up- or down-regulated post KLF4 WT induction (p&lt;0.001), indicating that KLF4 globally affected gene transcription (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Among them, a large fraction (500/613 = 82%) was only affected by KLF4 WT but not R458A, suggesting that these expression changes were regulated, directly or indirectly, via mCpG-dependent KLF4 binding activity (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Surprisingly, 308 of the 500 genes showed significantly elevated expression after KLF4 WT induction (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). For example, the expression of <italic>RHOC</italic>, <italic>RAC1</italic>, <italic>LMO7</italic>, and <italic>MIDN</italic> was up-regulated by induction of KLF4 WT but not R458A (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). This result suggested that mCpG-dependent KLF4-binding could activate cellular gene transcription and therefore, we decided to focus on these activated genes in the rest of our study.<fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.20068.006</object-id><label>Figure 3.</label><caption><title>Identify transcriptional network regulated by KLF4-mCpG interactions.</title><p>(<bold>A</bold>) RNA-seq data before (0 hr) and after (48 hr) KLF4 WT induction. The pink dots were determined as differential expressed genes (DEGs) (p&lt;0.001). (<bold>B</bold>) Overlap between DEGs in KLF4 WT and R458A cells, showing that a total of 613 genes were significantly regulated by KLF4 WT, 115 of which were also significantly regulated by KLF4 R458A. Among the rest 500 genes significantly regulated by KLF4 WT but not R458A (WT only DEGs), 308 of them were up-regulated by KLF4 WT only. (<bold>C</bold>) Four examples of KLF4 WT only DEGs. (<bold>D</bold>) Overlap between KLF4 WT and R458A KLF4 ChIP-seq peaks (48 hr +Dox), indicating that ~2733 peaks can be only bound by KLF4 WT; ~1157 peaks bound by both KLF4 WT and R458A, whereas R458A alone only bound a few new sites. (<bold>E</bold>) ChIP-Seq for KLF4 WT and R458A on and surrounding <italic>RHOC</italic> promoter as an example. RNA-seq at the same region was also shown, pre and post KLF4 WT and R458A induction, respectively. (<bold>F</bold>) Percentage of ChIP-seq peaks with mCpGs evaluated by whole genome bisulfite sequencing analysis. A significant enrichment was observed for methylated CpG in KLF4 WT-specific peaks (Blue bar) as compared to KLF4 R458A shared peaks (orange bar). (<bold>G</bold>) Motifs identified for KLF4-mCpG binding in KLF4 WT-specific peaks (Left) and for KLF4 R458A shared peaks (Right), respectively.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20068.006">http://dx.doi.org/10.7554/eLife.20068.006</ext-link></p><p><supplementary-material id="SD1-data"><object-id pub-id-type="doi">10.7554/eLife.20068.007</object-id><label>Figure 3—source data 1.</label><caption><title>Mapped reads for all the RNA-sequencing experiments.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20068.007">http://dx.doi.org/10.7554/eLife.20068.007</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-20068-fig3-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="SD2-data"><object-id pub-id-type="doi">10.7554/eLife.20068.008</object-id><label>Figure 3—source data 2.</label><caption><title>Mapped reads for the ChIP-sequencing experiments.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20068.008">http://dx.doi.org/10.7554/eLife.20068.008</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-20068-fig3-data2-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="SD3-data"><object-id pub-id-type="doi">10.7554/eLife.20068.009</object-id><label>Figure 3—source data 3.</label><caption><title>Chromosol location of KLF4 WT-specific, shared, and mutant-specific peaks.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20068.009">http://dx.doi.org/10.7554/eLife.20068.009</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-20068-fig3-data3-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="SD4-data"><object-id pub-id-type="doi">10.7554/eLife.20068.010</object-id><label>Figure 3—source data 4.</label><caption><title>Methylated 6-mer cis motifs identified in KLF4 WT-specific peaks.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20068.010">http://dx.doi.org/10.7554/eLife.20068.010</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-20068-fig3-data4-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20068-fig3-v2"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.20068.011</object-id><label>Figure 3—figure supplement 1.</label><caption><title>Analysis of RNA-seq and ChIP-seq data.</title><p>(<bold>A</bold>) High reproducibility of RNA-seq replicate. (<bold>B, C</bold>) Screenshots of RHOC and LMO7 ChIP-seq together with input line.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20068.011">http://dx.doi.org/10.7554/eLife.20068.011</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20068-fig3-figsupp1-v2"/></fig></fig-group></p><p>To determine which genes were directly activated by mCpG-dependent KLF4 binding events, we next performed genome-wide chromatin immunoprecipitation-sequencing (ChIP-seq) in KLF4 WT and R458A-expressing cells (i.e., 48 hr post induction). At least 70% of the ChIP-seq reads were mapped to the human genome (<xref ref-type="supplementary-material" rid="SD2-data">Figure 3—source data 2</xref>). A total of 3890 and 1222 significant ChIP-seq peaks were identified in KLF4 WT and R458A expressing cells, respectively (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). A comparison between the KLF4 WT and R458A ChIP-seq peaks identified that 2733 (70%) were specific to KLF4 WT, indicating that these peaks were recognized via mCpG-dependent KLF4 binding activity (referred as WT-specific peaks) (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). In contrast, ~95% of the KLF4 R458A ChIP-seq peaks were also recognized by KLF4 WT (referred as shared peaks), indicating that a single R458A mutation abolished &gt;2/3 of the KLF4 WT binding loci in the chromatins (<xref ref-type="supplementary-material" rid="SD3-data">Figure 3—source data 3</xref>). Sequence reads distribution of KLF4 WT and R458A ChIP-seq peaks at the promoter region of <italic>RHOC</italic>, as well as mapped <italic>RHOC</italic> RNA-seq, are shown in <xref ref-type="fig" rid="fig3">Figure 3E</xref> as an example. More examples can be found in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B,C</xref>.</p><p>To fully examine the DNA methylation status of the WT and R458A ChIP-seq peaks, we performed whole genome bisulfite sequencing to decode the methylome of U87 cells and combined the DNA methylome data separately with the KLF4 WT and R458A ChIP-seq datasets. We found that 66% of the KLF4 WT-specific ChIP-seq peaks showed a high methylation level (e.g., β &gt;60%) at CpG sites, while only 36% of the ChIP-seq peaks shared by KLF4 WT and R458A reached a similar CpG methylation level (p=3.7e-223). Different cutoffs for defining high methylation levels did not alter this observation (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). Therefore, the KLF4 WT-specific ChIP peaks are enriched for highly methylated CpGs.</p><p>Next, we carried out motif analysis to identify enriched and highly methylated 6-mer DNA motifs in WT-specific ChIP-seq peaks, as well as in shared ChIP-seq peaks. At a cutoff of β &gt;60% CpG methylation we found 10 methylated 6-mer motifs (<xref ref-type="supplementary-material" rid="SD4-data">Figure 3—source data 4</xref>) that were significantly over-represented in the WT-specific peaks (p=6.6e-37). Many of them share sequence similarity to the motif 5’-CCCGCC (<xref ref-type="fig" rid="fig3">Figure 3G</xref>; left panel), of which the methylated form was reported to be recognized by KLF4 in our previous study (<xref ref-type="bibr" rid="bib23">Hu et al., 2013</xref>). In contrast, the peaks shared by WT and R458A were found enriched for different motifs (e.g., 5’-AAAAGGAA and 5’- GAGTTGAA) (<xref ref-type="fig" rid="fig3">Figure 3G</xref>; right panel). Taken together, these results confirmed that the KLF4 WT-specific ChIP-seq peaks were enriched for highly methylated KLF4 binding motifs.</p></sec><sec id="s2-3"><title>Identification of direct targets of mCpG-dependent KLF4 interactions in GBM cells</title><p>To identify genes that were directly activated via mCpG-mediated KLF4 binding activity, we first searched the 2,733 KLF4 WT-specific ChIP-seq peaks against the genomic locations on those proximal regulatory regions, which were classified into three categories: upstream (~10 kb upstream to transcription start sites), 5’-UTRs, and exons. The proximal regulatory regions of 65 KLF4 WT up-regulated genes were found to be occupied by KLF4 WT-specific ChIP-seq peaks, indicating that they were direct targets of KLF4-mCpG interactions (<xref ref-type="supplementary-material" rid="SD5-data">Supplementary file 1</xref>).</p><p>We also noticed that most of the 2733 KLF4 WT-specific ChIP-seq peaks were located outside the proximal regulatory regions, suggesting that KLF4 might also activate gene expression via binding to distal enhancers. Therefore, we performed anti-H3K27ac ChIP-seq analysis and combined the obtained H3K27ac peaks with KLF4 WT-specific binding sites to identify the potential enhancer regions bound by KLF4 WT. 1773 out of 2733 KLF4 WT-specific ChIP-seq peaks overlapped with the 27,997 H3K27ac ChIP-seq peaks (64.5%) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Using an enhancer target prediction algorithm that connects enhancers to specific genes (enhanceratlas.org) (<xref ref-type="bibr" rid="bib17">Gao et al., 2016</xref>; <xref ref-type="bibr" rid="bib20">He et al., 2014</xref>), we identified 51 additional genes that were up-regulated via mCpG-dependent KLF4 binding events (<xref ref-type="supplementary-material" rid="SD5-data">Supplementary file 1</xref>). Therefore, the up-regulation of 116 genes was found directly associated with mCpG-dependent KLF4 binding to their <italic>cis</italic>-regulatory elements in the proximal regulatory regions (56%) and distal enhancers (44%) (<xref ref-type="fig" rid="fig4">Figure 4B</xref> and <xref ref-type="supplementary-material" rid="SD5-data">Supplementary file 1</xref>).<fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.20068.012</object-id><label>Figure 4.</label><caption><title>Downstream targets of KLF4-mCpG interactions.</title><p>(<bold>A</bold>) Overlap between KLF4 WT-specific ChIP peaks (2733) and the enhancer mark H3K27ac ChIP-seq peaks. A total of 1733 loci were identified. (<bold>B</bold>) A total of 116 KLF4-mCpG direct targets were identified in a serial of genome-wide studies. The overlap between WT-specific binding peaks (2733) and the 308 WT-only upregulated genes indicated that 20%, 24% and 12% of these genes were activated by KLF4 binding to mCpGs in gene upstream, 5’UTR and exon region, respectively. The overlap between enhancer regions in KLF4 WT-binding sites further identified 44% genes were activated by KLF4 binding to mCpGs in the enhancer regions. (<bold>C</bold>) Methylation level distribution of cis-elements in KLF4 binding peaks associated with 116 target genes. (<bold>D</bold>) Bisulfite sequencing confirmed DNA methylation in some of the KLF4 WT-specific binding peaks. (<bold>E</bold>) Gene ontology analysis of direct targets of KLF4-mCpG indicated that these targets have been implicated in cell adhesion, migration, cytoskeleton arrangement and cell binding activities. (<bold>F</bold>) Boxplot of gene expression for WT, WT+Dox, WT + 5 Aza, and WT + 5-Aza+Dox (<bold>G</bold>) Histogram of FC (after and before Dox) difference with and without 5-Aza for 116 target genes and all expressed genes, respectively.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20068.012">http://dx.doi.org/10.7554/eLife.20068.012</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20068-fig4-v2"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.20068.013</object-id><label>Figure 4—figure supplement 1.</label><caption><title>Bisulfite sequencing of the cis-regulatory elements of additional KLF4-mCpG direct targets.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20068.013">http://dx.doi.org/10.7554/eLife.20068.013</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20068-fig4-figsupp1-v2"/></fig></fig-group></p><p>We next examined whether this association was statistically significant. We first focused on 12,824 genes that were expressed (FPKM &gt;0.5) in U87 cells, among which 308 (2.4%) genes were found up-regulated only in KLF4 WT-induced cells. Meanwhile, we observed that KLF4 mCpG-dependent binding peaks were associated with 2518 expressed genes, of which 116 (4.6%) were up-regulated genes that is significantly higher than the ratio of expressed genes not associated with KLF4 WT binding sites (fold enrichment = 1.9; p=5.0e-13).</p><p>To directly assess the methylation status in the <italic>cis</italic>-regulatory elements of the 116 direct target genes, we integrated the methylome dataset and found that the majority (72%) of the 116 genes were indeed associated with highly methylated (β &gt; 0.6) <italic>cis</italic>-regulatory elements (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). To confirm this observation, we randomly selected 15 loci and performed methylation analysis by Sanger sequencing. Ten of them were confirmed to contain highly (75–100%) methylated CpG sites in the associated <italic>cis</italic>-regulatory elements. A few examples are shown in <xref ref-type="fig" rid="fig4">Figure 4D</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</p><p>Gene Ontology analysis showed that these 116 direct targets of KLF4 WT were significantly enriched in biological processes relevant to the observed phenotypes, such as cell communication, regulation or establishment of localization, cell adhesion or morphogenesis, positive regulation of MAP kinase activity, cell-cell junction, and cytoskeleton organization (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). These results suggest that KLF4 could bind to methylated <italic>cis</italic>-regulatory elements to up-regulate crucial genes involved in tumor cell migration.</p><p>To examine the impact of global DNA demethylation on the expression level of KLF4-mCpG direct target genes, we performed whole genome RNA-seq in the presence of 5-Aza treatment. We observed that in the presence of 5-Aza, KLF4 WT induction did not activate 116 target genes significantly as that in the absence of 5-Aza (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). Actually, the expression level of 101 of the 116 genes was reduced in 5-Aza treated cells as compared with untreated cells (<xref ref-type="fig" rid="fig4">Figure 4G</xref>), while about half (53%) of all expressed genes were down-regulated after 5-Aza treatment (p=1.2e-14), suggesting that DNA methylation is responsible for the transcription activation of these 101 genes targeted by KLF4-mCpG binding. These results further supported the conclusion that DNA methylation is directly involved in KLF4 binding and gene activation.</p></sec><sec id="s2-4"><title>KLF4-mCpG interactions activate <italic>RHOC</italic> via chromatin remodeling</title><p>To firmly establish the causality between mCpG-dependent KLF4 binding to <italic>cis</italic>-regulatory elements and transcription activation, we decided to focus on two important genes, namely <italic>RHOC</italic> and <italic>RAC1</italic>, for in-depth characterization. They encode two small GPTases that are known to play critical roles in cell migration and adhesion, and were found multiple times in the enriched GO terms as described above (<xref ref-type="bibr" rid="bib26">Karlsson et al., 2009</xref>). For example, RHOC activation leads to F-actin stress fiber formation and the assembly of focal adhesion complexes. Studies reveal that there are no known <italic>RHOC</italic> pathogenic mutations found in cancers, however, biologically relevant aberrant levels of <italic>RHOC</italic> expression are common, and there is a strong association between <italic>RHOC</italic> expression levels and poor prognosis (<xref ref-type="bibr" rid="bib26">Karlsson et al., 2009</xref>; <xref ref-type="bibr" rid="bib34">Narumiya et al., 2009</xref>). An examination of the ChIP-seq datasets at the promoter regions of <italic>RHOC</italic> and <italic>RAC1</italic> indicated differential binding by KLF4 WT and R458A. Moreover, genome-wide bisulfite sequencing confirmed that these peaks contained highly methylated CpGs and these peaks were in close proximity to the coding regions of <italic>RHOC</italic> (−507 bp to TSS) and <italic>RAC1</italic> (−922 bp to TSS).</p><p>In the case of <italic>RHOC</italic>, we first showed that induction of KLF4 WT, but not the R458A mutant, could induce RHOC at both mRNA and protein levels using RT-PCR and immunoblot analysis, respectively (<xref ref-type="fig" rid="fig5">Figure 5A,B</xref>). Using a primer pair flanking this ChIP-seq peak, we confirmed that this fragment could be ChIP-ed substantially better with the KLF4 WT than the R458A mutant (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). To further establish causality of DNA methylation-dependent binding of KLF4 on induction of its target genes, we performed bisulfite sequencing against this <italic>cis</italic>-regulatory element with and without the 5-Aza treatment. We observed that four of the five CpG in this region were 100% methylated; however, after the 5-Aza treatment the methylation levels of the four CpGs was reduced to various levels, ranging from 13–80% (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Most importantly, reduction of methylation almost completely abolished KLF4 WT binding to this <italic>cis</italic>-regulatory element (<xref ref-type="fig" rid="fig5">Figure 5E</xref>), and RHOC protein level was also significantly repressed (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). The same set of assays was also carried out to analyze the <italic>cis</italic>-regulatory elements of <italic>RAC1</italic> and the same results were obtained (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Therefore, high methylation levels in <italic>RHOC</italic> and <italic>RAC1</italic> promoters were essential for KLF4 WT to activate their gene transcription.<fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.20068.014</object-id><label>Figure 5.</label><caption><title>KLF4-mCpG binding activity activates RHOC expression by chromatin remodeling.</title><p>(<bold>A</bold>) Real-time PCR indicated that <italic>RHOC</italic> RNA was significantly upregulated by KLF4 WT but not R458A (+Dox, 48 hr, ***p&lt;0.001). (<bold>B</bold>) RHOC protein expression was upregulated by KLF4 WT only; fold changes were listed under the blots. (<bold>C</bold>) A KLF4 antibody was used to precipitate crosslinked genomic DNA from cells expressing KLF4 WT and R458A. Rabbit IgG was used to control for non-specific binding. De-crosslinked DNA samples were served as the input for PCR. The <italic>RHOC</italic> promoter was only enriched in the ChIP’ed samples from KLF4 WT expressing cells. In contrast, a known KLF4 binding site on B2R promoter was used as a positive control, and detected in the ChIP’ed samples from both KLF4 WT and R458A expressing cells. A non-promoter sequence was selected as a negative control (Neg) and no band was detected. (<bold>D</bold>) Bisulfite sequencing of <italic>RHOC</italic> promoter region: each row represents one sequenced clone; each column represents one CpG site; filled circles stand for methylation. All 7 clones showed 100% methylation at four CpG sites in the <italic>RHOC</italic> promoter (~507 bp upstream from TSS). The DNMT inhibitor 5-Aza pretreatment partially reversed DNA methylation in the <italic>RHOC</italic> promoter region. (<bold>E</bold>) ChIP-PCR indicated that 5-Aza greatly abolished KLF4 WT binding to <italic>RHOC</italic> promoter region when hypomethylated. (<bold>F</bold>) Immunobloting analysis showed that KLF4 WT-induced RHOC up-regulation was blocked by pretreatment with 5-Aza. (<bold>G</bold>) KLF4-mCpG interactions in <italic>RHOC</italic> promoter region triggered histone mark changes. Tet-on KLF4 WT cells were treated with Dox for 48 hr, and genomic DNA from cells before and after Dox treatment were ChIP’ed with antibodies recognizing different histone marks and amplified for the RHOC promoter region. KLF4-mCpG interactions were associated with an increase in the active mark H3K27ac and a decreased in the repressive marks H3K27me3 and H3K9me3. Disrupted KLF4-mCpG interactions in KLF4 R458A expressing cells did not show changes in these histone marks in the <italic>RHOC</italic> promoter region.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20068.014">http://dx.doi.org/10.7554/eLife.20068.014</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20068-fig5-v2"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.20068.015</object-id><label>Figure 5—figure supplement 1.</label><caption><title>Methylated DNA in the <italic>cis</italic>-regulatory region of <italic>RAC1</italic> determined KLF4 binding and <italic>RAC1</italic> upregulation.</title><p>(<bold>A, B</bold>) RT-PCR and Western blot showed RAC1 was significantly up-regulated by KLF4 WT at both the mRNA and protein level. (<bold>C</bold>) ChIP-PCR showing KLF4 and <italic>RAC1</italic> promoter binding. Compared to KLF4 R458A cells, there is an enrichment of KLF4-<italic>RAC1</italic> promoter binding in KLF4 WT expressing cells. (<bold>D</bold>) Bisulfite sequencing of the <italic>RAC1</italic>-KLF4 binding site before and after 5-Aza treatment. <italic>RAC1</italic> promoter was heavily methylated, whereas 5-Aza abolished methylation on these sites. (<bold>E</bold>) ChIP-PCR of KLF4-<italic>RAC1</italic> promoter interactions in the presence of 5-Aza in KLF4 WT cells. 5-Aza treatment prevented KLF4 binding to the <italic>RAC1</italic> promoter region when demethylated. (<bold>F</bold>) RT-PCR showing 5-Aza reversed KLF4 WT-mediated <italic>RAC1</italic> up-regulation.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20068.015">http://dx.doi.org/10.7554/eLife.20068.015</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20068-fig5-figsupp1-v2"/></fig></fig-group></p><p>Because DNA methylation is usually considered to be associated with repressive histone marks to maintain downstream gene silencing, our observation suggested that the recruitment of KLF4 WT to the methylated <italic>RHOC</italic> promoter altered chromatin status in order to activate <italic>RHOC</italic> transcription. Based on KLF4’s interaction with histone modifying enzymes, we examined the status of an active (H3K27ac) and two repressive (H3K27me3 and H3K9me3) histone marks at the <italic>RHOC</italic> promoter regions. We also monitored histone mark changes before (0 hr) and after (48 hr) KLF4 induction. We observed that upon KLF4 binding to DNA (48 hr post Dox), the active mark H3K27ac was significantly increased by ~2.5 fold. On the other hand, both repressive marks, H3K9me3 and H3K27me3, were decreased by ~3.5 and~6 fold, respectively (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). As a comparison, KLF4 R458A induction failed to trigger any detectable changes in H3K27ac, H3K9me3, or H3K27me3 marks in the <italic>RHOC</italic> promoter region (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). Thus, the recruitment of KLF4 WT to the methylated <italic>RHOC</italic> promoter initiated conversion from repressive to active chromatins, as a prerequisite for activation of <italic>RHOC</italic> transcription.</p></sec><sec id="s2-5"><title>KLF4-mCpG interactions globally affect chromatin status</title><p>To determine whether KLF4 WT activated its other direct targets via chromatin remodeling as described above, we performed ChIP-seq analysis against one active (H3K27ac) and two repressive (H3K9me3 and H3K27me3) histone marks before (0 hr) and after (48 hr) KLF4 WT induction. For all of the three marks, we observed remarkable dynamic changes, centered around the 162 KLF4 WT ChIP-seq peaks associated with the 116 direct targets of KLF4-mCpG (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Specifically, H3K27ac level increased in 83.3% of the 162 peaks at 48 hr (<xref ref-type="fig" rid="fig6">Figure 6B</xref>, p=7.2E-19). In contrast, H3K27me3 and H3K9me3 levels decreased in 54.3% (p=3.4E-2) and 63.6% (p=1.5E-4) of the 162 peaks at 48 hr, respectively (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). As a negative control, we examined the H3K27ac dynamic changes in the up-regulated genes shared by KLF4 WT and R458A. Only 36% of the shared KLF4 peaks (22/60) had stronger H3K27ac signal after 48 hr of Dox treatment (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A–C</xref>), suggesting that KLF4-mCpG binding enhances H3K27ac.<fig-group><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.20068.016</object-id><label>Figure 6.</label><caption><title>Methyl-mCpG dependent KLF4 binding activity triggers chromatin remodeling to activate gene expression.</title><p>(<bold>A</bold>) Heatmaps of histone mark signals, H3K27ac, H3K27me3, and H3K9me3, before and after KLF4-mCpG interactions (0 vs. 48 hr), respectively, ±3 kb surrounding 162 KLF4 ChIP peaks, which were associated with the 116 KLF4-mCpG direct targets. The peaks were sorted by their average signals at 48 hr for each histone mark. (<bold>B</bold>) The signal difference of histone marks between 48 hr and 0 hr, sorted from minimum to maximum. Over 83% of the 162 peaks had increased H3K27ac signals (p=7.2E-19), whereas 54.3% (p=3.4E-2) and 63.6% (p=1.5E-4) of the peaks had decrease in H3K27me3 and H3K9me3 signals, respectively. (<bold>C</bold>) Stronger H3K27ac signals were accumulated surrounding the KLF4 WT ChIP-seq peak on gene <italic>LMO7</italic>, at 48 hr after KLF4 WT induction; whereas no significant change in H3K27ac signals was observed in R458A expressing cells, as the R458A mutation abolished KLF4-mCpG binding ability. (<bold>D</bold>) Genome-wide analysis of dynamic changes of H3K27ac peaks before and after KLF4 WT or R458A induction, respectively. A total of 3593 new H3K27ac peaks appeared after KLF4 WT induction (upper panel), whereas only 131 new peaks were generated in KLF4 R458A expressing cells (lower panel), indicating that mCpG-dependent KLF4 binding activity caused chromatin remodeling to activate gene expression.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20068.016">http://dx.doi.org/10.7554/eLife.20068.016</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20068-fig6-v2"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.20068.017</object-id><label>Figure 6—figure supplement 1.</label><caption><title>Dynamic changes of histone mark H3K27ac signal in the shared KLF4 peaks.</title><p>(<bold>A</bold>) Heatmaps of H3K27ac signals around 60 shared peaks, corresponding to up-regulated genes by KLF4 WT and R458A. (<bold>B and C</bold>) Only 36% (22/60) of the shared peaks was associated with an increase in H3K27ac, whereas there were more than 83% (135/162) of the WT-specific peaks associated with increased H3K27ac.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20068.017">http://dx.doi.org/10.7554/eLife.20068.017</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20068-fig6-figsupp1-v2"/></fig></fig-group></p><p>To further confirm that mCpG-mediated KLF4 binding caused chromatin remodeling on a genome-wide scale, we compared the H3K27ac ChIP-seq data obtained before (0 hr) and after (48 hr) KLF4 WT and R458A induction. An example was shown in <xref ref-type="fig" rid="fig6">Figure 6C</xref>. After KLF4 WT was recruited to intron region of LMO7, which is known to play a role in cell migration and adhesion (<xref ref-type="bibr" rid="bib22">Hu et al., 2011</xref>), the H3K27ac level was significantly increased around the KLF4 ChIP-seq peak. In contrast, R458A mutation abolished the KLF4 binding at the same locus. As a result, the H3K27ac level remained low after R458A induction.</p><p>Overall, in KLF4 WT-induced cells, 3593 novel H3K27ac peaks were generated, while only a negligible number of H3K27ac peaks (41) disappeared at 48 hr of KLF4 WT induction (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). Among the 3593 novel H3K27ac peaks, 274 were found in the flanking regions of KLF4 ChIP-seq peaks (p=3.5E-5). In contrast, induction of R458A did not yield noticeable changes in H3K27ac peak numbers. Taken together, these results suggest that mCpG-mediated KLF4 binding events induced the changes of histone modification and gene activation.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Abnormal DNA methylation has been found in many cancer types including glioblastoma. Contrary to traditional view of DNA methylation in gene silencing, recent survey of methylome and gene expression profiling demonstrated that the promoters of as many as 20% highly expressed genes in tumors are methylated at CpG sites, suggesting that at least in some cases, DNA methylation positively correlates with gene expression (<xref ref-type="bibr" rid="bib14">Feinberg, 2014</xref>, <xref ref-type="bibr" rid="bib13">2007</xref>). Although previous studies suggested that many TFs could interact with methylated DNA in vitro, it remains elusive whether such mCpG-dependent binding activity plays any significant physiological role in cells. To address this question, we took advantage of the R458A mutation that abolished KLF4’s mCpG-dependent binding activity to dissect the functional impact of TF-mCpG interactions. We demonstrated that several strong phenotypes, ranging from cell morphology to cell adhesion and migration, were dependent on this newly discovered activity of KLF4. Using a series of in vivo assays coupled with bioinformatics analyses, we further showed that KLF4 could gain access to the inactive chromatin regions via binding to methylated DNA motifs and consequently, led to conversion from repressive to active histone marks and much enhanced transcription of the direct gene targets of KLF4 (<xref ref-type="fig" rid="fig7">Figure 7</xref>). Thus, we are the first to provide genome-wide evidence that recruitment of KLF4 to methylated <italic>cis</italic>-regulatory elements resulted in a global chromatin remodeling (i.e., from repressive to active states), which contradicts the classic view that CpG methylation is a result of chromatin remodeling (i.e., from active to repressive states).<fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.20068.018</object-id><label>Figure 7.</label><caption><title>Working model of KLF4 binds to methylated <italic>cis</italic>-regulatory elements, followed by chromatin remodeling and transcription activation.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20068.018">http://dx.doi.org/10.7554/eLife.20068.018</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20068-fig7-v2"/></fig></p><p>Whereas many proteins have been found to recognize methylated DNA, the causality between DNA methylation and TF binding is not always straightforward. It has been reported that TF binding could change methylation status of <italic>cis</italic>-regulatory elements (<xref ref-type="bibr" rid="bib15">Feldmann et al., 2013</xref>), which suggests that KLF4-mCpG binding could be the secondary effect of gene transactivation. To rule out the possibility that KLF4 binding results in methylation of its targeted genes, we performed bisulfite sequencing in tet-on KLF4 WT cells before and after KLF4 induction (0 hr and + Dox 48 hr). Unchanged methylation level in KLF4 binding site (e.g. <italic>RHOC</italic> promoter region) indicated that methylation is not a consequence of KLF4 binding (data not shown). Other forms of cytosine modification, including 5-hydroxymethyl-cytosine (5-hmC), 5-formylcytosine, and/or 5-carboxylcytosine also exist in cells (<xref ref-type="bibr" rid="bib43">Tan and Shi, 2012</xref>). This will not affect our conclusion appreciably since KLF4 does not bind to 5-hmC (<xref ref-type="bibr" rid="bib42">Spruijt et al., 2013</xref>).</p><p>We are fully aware that 5-Aza is only a sub-optimal approach to examine the effect of specific methylation sites, because it induces global demethylation and may have some non-specific effects (<xref ref-type="bibr" rid="bib8">Christman, 2002</xref>). However, we have multiple lines of evidences showing that the observed phenotypes are due to specific interactions between KLF4 and methylated sites. (1) In our control experiments when KLF4 R458A cells were treated with 5-Aza, we did not see changes in gene expression and cell migration. (2) In the focused studies of <italic>RHOC</italic> and <italic>RAC1</italic>, we showed that DNA methylation is responsible for KLF4 binding and gene activation. <italic>RHOC</italic> and <italic>RAC1</italic> are major GTPase involved in cell migration and motility. (3) Comparison of ChIP-seq between KLF4 WT and R458A showed that WT-specific binding sites are enriched for highly methylated sites. Given the phenotypic differences between KLF4 WT and R458A, the result suggested that the observed phenotypes in WT are likely due to specific interactions between KLF4 and DNA methylation sites. (4) Our new RNA-seq data in the presence of 5-Aza also indicated that 5-Aza globally reversed the up-regulation of many KLF4-mCpG targets.</p><p>In our study, we placed a higher priority on KLF4-mCpG-mediated gene transactivating effect, as this will be most paradigm-shifting based on current understandings that CpG methylation results in gene silencing. Here we found that KLF4 recognizes mCpG at proximal and enhancer regions to activate gene expression. Many questions remain regarding how DNA methylation, a repressive epigenetic mark, activates gene expression. In cells, opening the chromatin structure is often the first step for gene transcription (<xref ref-type="bibr" rid="bib9">Cirillo et al., 2002</xref>; <xref ref-type="bibr" rid="bib31">Lupien et al., 2008</xref>). KLF4 is one of the pioneer TFs in somatic reprogramming that interact with condensed chromatin and recruit histone-modifying enzymes to enable gene expression (<xref ref-type="bibr" rid="bib4">Buganim et al., 2013</xref>; <xref ref-type="bibr" rid="bib24">Iwafuchi-Doi and Zaret, 2014</xref>). Yet, exactly how these pioneer TFs gain access to condensed, highly methylated DNA is still unknown (<xref ref-type="bibr" rid="bib10">Drouin, 2014</xref>). Although recent studies showed that pioneer transcription factors, including KLF4, are capable of recognizing partial motifs located in the heterochromatins, our study, for the first time, demonstrated that the pioneer transcription factor KLF4 could actually bind to methylated motifs located in repressive chromatins, providing an alternative mechanism for pioneer factors interacting with repressive chromatin. Our data support a new model in which TF-mCpG binding communicates with histone modifications to initiate gene transcription. The cross-talk between DNA methylation and histone modifications in gene regulation will open up a new avenue for determining how epigenetic mechanisms drive physiology and pathophysiology including tumor malignancy.</p><p>In summary, TF binding to methylated regions of the genome to activate gene transcription is a new paradigm supported by several studies (<xref ref-type="bibr" rid="bib16">Filion et al., 2006</xref>; <xref ref-type="bibr" rid="bib32">Mann et al., 2013</xref>; <xref ref-type="bibr" rid="bib37">Rishi et al., 2010</xref>; <xref ref-type="bibr" rid="bib39">Sasai et al., 2010</xref>; <xref ref-type="bibr" rid="bib40">Serra et al., 2014</xref>; <xref ref-type="bibr" rid="bib42">Spruijt et al., 2013</xref>). Our work is the first to demonstrate such gene activation mechanism can mediate physiological functions in biologically relevant systems (<xref ref-type="bibr" rid="bib51">Zhu et al., 2016</xref>). We further demonstrated that mCpG dictates TF binding, histone modifications and gene activation in a sequence-specific manner, thereby influencing cancer cell phenotypes. Our study reveals that mCpG-dependent binding activity of KLF4 serves as a link between methylated CpG and changes in chromatin status (<xref ref-type="bibr" rid="bib6">Charlet et al., 2016</xref>), two most important epigenetic mechanisms in gene regulation. In all, our study provides a new paradigm in which TFs can act as a new class of DNA methylation readers/effectors that drive gene transactivation and diverse biological processes.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Cell culture and reagents</title><p>All reagents were purchased from Sigma Chemical Co. (St. Louis, MO) unless otherwise stated. The human glioblastoma (GBM) cell lines U87 (CLS Cat# 300367/p658_U-87_MG, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_0022">CVCL_0022</ext-link>) and U373 (ATCC Cat# HTB-17, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_2219">CVCL_2219</ext-link>) were originally purchased from ATCC (Manassas, VA) and cultured in our laboratory. Both cell lines are free from mycoplasma and authenticated with short tandem repeat (STR) profiling by Johns Hopkins Genetic Resources Core facility using Promega GenePrint 10 system (Madison, WI). U87 cells were cultured in Minimum Essential Media (MEM, Thermo Fisher Scientific, Grand Island, NY) supplemented with sodium pyruvate (1%), sodium bicarbonate (2%), non-essential amino acid (1%) and 10% fetal calf serum (FCS, Gemini Bio-products, West Sacramento, CA). U373 cells were cultured in Dulbecco’s Modified eagle medium (DMEM, Thermo Fisher Scientific) supplemented with 2% (4-(2-hydroxyethyl)−1-piperazineethanesulfonic acid (HEPES) and 10% FCS. Cells were incubated in a humidified incubator containing 5% CO<sub>2</sub>/95% air at 37°C, and passaged every 4–5 days.</p></sec><sec id="s4-2"><title>Engineering tet-on GBM cells expressing KLF4 WT and KLF4 R458A</title><p>KLF4 WT and R458A constructs were inserted into a doxycycline-inducible TripZ lentiviral vector (Thermo Fisher Scientific) (<xref ref-type="bibr" rid="bib48">Ying et al., 2011a</xref>). Virus was packaged using the Viral Power Packaging system (Thermo Fisher Scientific) according to the manufacturer’s forward transfection instructions. Virus were collected by centrifuging at 3000 rpm for 15 min. GBM stable cell lines were established by transfecting the cells with lentivirus harboring tet-on KLF4 WT or KLF4 R458A constructs and selected with puromycin (1 µg/ml). The introduction of doxycycline (Dox) to the system initiates the transcription of the genetic product. Cells without doxycycline treatment serve as controls for KLF4 function.</p></sec><sec id="s4-3"><title>Immunoblot and immunocytochemistry</title><p>Immunoblot analysis was used to examine KLF4 protein expression. To collect whole cell protein, cells were lysed with RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% Na-deoxycholate) containing protease and phosphatase inhibitors (EMD Millipore, Billerica, MA) and sonicated for 15 s; the suspensions were centrifuged at 3000 <italic>g</italic> for 10 min. Thirty micrograms of protein were separated using 4–20% SDS-PAGE gels (Lonza, Williamsport, PA) and blotted onto nitrocellulose membranes (<xref ref-type="bibr" rid="bib36">Reznik et al., 2008</xref>). Membranes were incubated in Odyssey Licor blocking buffer (LI-COR Biosciences, Lincoln, NE) for 1 hr at room temperature and then overnight with primary antibodies at 4°C in Odyssey blocking buffer. After rinsing, membranes were incubated with IRDye secondary antibodies (1:15000-1:20,000, LI-COR Biosciences) and protein expression changes were quantified by dual wavelength immunofluorescence imaging (Odyssey Infrared Imaging System, LI-COR Biosciences) as previously described (<xref ref-type="bibr" rid="bib49">Ying et al., 2011b</xref>). Antibodies were purchased from: anti-KLF4 (Santa-Cruz, Dallas, Texas); anti-RHOC (Cell signaling, Danvers, MA); and anti-RAC1 (Cell signaling).</p><p>For staining, GBM cells grown on glass slides were fixed with 4% paraformaldehyde for 30 min at 4°C and permeabilized with PBS containing 0.1% Triton X-100 for 10 min. The cells were then incubated with primary antibodies at 4°C overnight and then incubated with appropriate corresponding secondary antibodies conjugated with Alex Flourescent 488 or cy3 for 30 min at room temperature. For double staining with F-actin, Alex Flourecent 647-conjugated phalloindin (1 unit, Thermo Fisher Scientific) was used to incubate with the cells. Slides were mounted with Vectashield Antifade solution containing DAPI (Vector Laboratories, Burlingame, CA) and observed under fluorescent microscopy. Immunofluorescent images were taken and analyzed using Axiovision software (Zeiss, Germany).</p></sec><sec id="s4-4"><title>Cell adhesion and migration assay</title><p>For adhesion assay, twenty-four well plates were blocked with Dulbecco's Modified Eagle <italic>Medium</italic> (DMEM) containing 0.5% bovine serum albumin (BSA) for 1 hr at 37°C followed by plating GBM cells at a density of 4 × 10<sup>5</sup> cells/well. After 1 hr incubation at 37°C, plates were shaken at 2000 rpm for 15 s, washed twice with pre-warmed DMEM medium containing 0.1% BSA, and the number of remaining adherent cells were measured with MTT assays (<xref ref-type="bibr" rid="bib47">Xia et al., 2005</xref>).</p><p>For migration assays in transwells (Corning, Lowell, MA), GBM cells were suspended at 1 × 10<sup>6</sup> cells/ml; 100 microliters of the cell suspension were added to the upper chamber of the transwells in serum-free medium (<xref ref-type="bibr" rid="bib46">Wang et al., 2012</xref>). Six hundred microliters of medium containing 10% FCS was added to the lower chamber. After 3 hr incubation at 37°C, cells were fixed with Diff-Quick kit (Thermo Fisher Scientific). Cells on the upper side of the transwells were gently wiped off with Q-tips. Cells migrating through the filter were stained with 4'−6-Diamidino-2-phenylindole (DAPI). Migration was quantified by counting cells on five selected fields of view per transwell in at least three independent experiments (<xref ref-type="bibr" rid="bib46">Wang et al., 2012</xref>).</p><p>For wound healing assays, GBM cells were grown under 10% FCS medium in 35 mm dishes until confluent. Cell proliferation was inhibited by mitomycin C (1 µg/ml) for half hour. Several scratches were created using a 10 μl pipette tip through the confluent cells. Dishes were washed with PBS for three times and cells were grown in 0.1% FCS medium for 24–48 hr. Phase contrast pictures were taken at different time points. The width of the scratch was measured and quantified as previously described (<xref ref-type="bibr" rid="bib18">Goodwin et al., 2010</xref>).</p></sec><sec id="s4-5"><title>Reverse-transcriptase PCR and quantitative real-time PCR</title><p>Total RNA (1 µg) was reverse-transcribed using the oligo (dT)12–18 primer and Superscript II (Thermo Fisher Scientific) according to the manufacturer's instructions. The thermal cycling conditions were as follows: 95°C, 5 min, followed by 30 cycles of 95°C for 10 s, 55°C for 10 s, and ended with 72°C for 30 s.</p><p>Data were analyzed using parametric statistics with one-way ANOVA. Post-hoc tests included the Students T-Test and the Tukey multiple comparison tests as appropriate using Prism (GraphPad, San Diego, CA). All experiments reported here represent at least three independent replications. All data are represented as mean value ± standard error of mean (S.E.) significance was set at p&lt;0.05.</p></sec><sec id="s4-6"><title>Genome-wide profiling of gene expression and KLF4 binding in GBM cells</title><sec id="s4-6-1"><title>RNA-seq</title><p>RNAs from KLF4 WT and R458A-expressing cells (0 hr and 48 hr +Dox) was subjected to Illumina HiSeq next generation sequencing following the standard amplification and library construction protocol provided by the Johns Hopkins Deep Sequencing and Microarray Core Facility. Sequencing was performed using 76-base single-end reads, with 23- to 33 million reads generated from each sample. We first used Tophat2 to map all reads to human genome (hg19) then employed Cufflink to summarize the gene/transcript expression based on mapped reads. An R package, DEGseq, was taken to identify DEGs for p&lt;0.001 between 0 hr and 48 hr in KLF4 WT and R458A cells, respectively.</p></sec></sec><sec id="s4-7"><title>Whole genome bisulfite sequencing (WGBS) analysis</title><p>We employed the software package bismark (<xref ref-type="bibr" rid="bib27">Krueger and Andrews, 2011</xref>) to perform WGBS analysis. First we built bismark reference human genome, then mapped sequence reads onto these specific references. Two files were generated afterwards. The text file includes the summary about total reads, mapping efficiency, total methylated C’s in CpG/CHG/CHH context. The other file in the same format was used for next step to extract methylation. Finally, we used bismark2bedGraph followed by coverage2cytosine to achieve the methylated and unmethylated reads of all CpG sites. The β value was calculated for each CpG site as the ratio of number of methylated reads to sum over methylated and unmethylated.</p><sec id="s4-7-1"><title>Motifs analysis</title><p>To identify methylated motifs enriched in KLF4 WT-specific peaks, we first used WGBS information to selected all 6-mers including mCpG (β &gt;0.6), then enumerated these 6-mers to compare their occurrence in 2733 KLF4 WT-specific peaks and all KLF4 binding peaks. The p-values were calculated based on hypergeometric model to represent the significance of methylated 6-mers’ frequencies in KLF4 WT-specific peaks compared to all, followed by multiple-test Bonferroni correction. The 6-mers with p&lt;0.01 were selected to construct the motif logo. The package, MEME (Multiple EM for Motif Elicitation) (<xref ref-type="bibr" rid="bib2">Bailey and Elkan, 1994</xref>), was used to evaluate motifs significantly over-represented in KLF4 shared peaks, compared to all KLF4 binding peaks.</p></sec><sec id="s4-7-2"><title>Gene ontology analysis</title><p>Gene Ontology analysis (<xref ref-type="bibr" rid="bib1">Ashburner et al., 2000</xref>) was performed for the 116 differential expressed genes (DEGs) up-regulated by WT only, compared to that for total 12,824 genome-wide expressed genes (FPKM &gt;0.5). The statistical significance of the enrichment was evaluated by p-value based on hypergeometric distribution model. The p-values were then adjusted by multiple-test correction via false discovery rate (FDR). A cutoff of FDR &lt; 0.05 was used to identify significantly enriched GO terms.</p></sec><sec id="s4-7-3"><title>Chromatin immunoprecipitation (ChIP)-seq</title><p>A commercial ChIP-grade anti-KLF4 antibody (H180; Santa Cruz) recognizing the N-terminal region of KLF4 (DNA-binding domains of KLF4 are located to the very C-terminus) was used for ChIP. Tet-on KLF4 WT and R458A cells were treated with Dox for 48 hr followed by ChIP using the anti-KLF4 antibody and Dynabeads Protein A/G (Thermo Fisher Scientific) according to a protocol described previously (<xref ref-type="bibr" rid="bib23">Hu et al., 2013</xref>). DNA library construction and sequencing was performed at Johns Hopkins Deep Sequencing and Microarray Core Facility. The antibodies used for ChIP experiments were as follows: anti-KLF4 (Santa Cruz, H-180, sc-20691); anti-H3K27ac (Abcam, ab4279) (<xref ref-type="bibr" rid="bib19">Hawkins et al., 2010</xref>); anti-H3K27me3 (Millipore, 07–449) (<xref ref-type="bibr" rid="bib19">Hawkins et al., 2010</xref>) and anti-H3K9me3 (Abcam, ab8898) (<xref ref-type="bibr" rid="bib19">Hawkins et al., 2010</xref>).</p><p>KLF4 ChIP-Seq data were mapped by Bowtie2, followed by MACS 1.4 being used to call peaks with cutoff of p&lt;1E-5. We first obtained binding peaks for KLF4 WT and R458A, respectively. The peaks identified for both KLF4 WT and R458A at the same locus were referred as shared KLF4 binding peaks. Then we used KLF4 WT as foreground and R458A as background control to call peaks again. The new peaks were marked as KLF4 WT-specific ChIP peaks, only if they were not overlapped with shared ones which had been already identified. Same approach was used to obtain R458A specific binding peaks for which the foreground was KLF4 R458A ChIP-Seq data compared to the background of KLF4 WT ChIP-seq data.</p><p>We utilized MACS2 to recognize broad peaks of H3K27ac based on their ChIP-Seq data mapped by Bowtie2. The cutoff of broad peak call was q &lt; 0.1. The same procedure as that for KLF4 ChIP-Seq was taken to distinguish H3K27ac peaks at 0 hr only, at 48 hr only, or shared at both 0 hr and 48 hr, for KLF4 WT and R458A, respectively.</p></sec><sec id="s4-7-4"><title>Quantitative study of histone modification</title><p>We chose two sets of genomic regions to quantitatively study dynamic changes of histone modification between 48 hr and 0 hr. The first group is regions within ±1 kb from the middle points of KLF4 binding peaks. As negative control, we selected other 7780 regions, which locate 4 kb to 6 kb away from the boundaries of 3890 KLF4 binding peaks, then removed 558 out of 7780 regions in the negative control group which overlap with at least one of KLF4 binding peaks. The signal of the histone modification within the region was represented by RPM (Reads per Million) in logarithmic scale base 2. The difference of signals between 48 hr and 0 hr was further normalized so that the difference for 7222 random regions was 50% up and 50% down.</p><p>All the raw data for our large-scale studies have been deposited in GEO (GSE97632).</p></sec></sec><sec id="s4-8"><title>Assessment of CpG methylation status by bisulfite sequencing</title><p>Sanger bisulfite sequencing was performed as previously described (<xref ref-type="bibr" rid="bib23">Hu et al., 2013</xref>). Purified genomic DNA from GBM cells were treated by EZ DNA Methylation-Direct Kit (Zymo Research, Irvine, CA). After bisulfite conversion, regions of interest were PCR-amplified using Taq polemerase. The primers used for bisulfite sequencing were listed in <xref ref-type="supplementary-material" rid="SD6-data">Supplementary file 2</xref>. PCR products were gel-purified and cloned into a TA vector (Thermo Fisher Scientific). Individual clones were sequenced (Genewiz, Cambridge, MA) and aligned with the reference sequence.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Dr. J Laterra for critical reading and H Lopez-Bertoni for technical expertise. This work was supported by grants from NIH R01NS091165 (SX), EY024580 (JQ), EY023188 (JQ), GM111514 (HZ and JQ), R01 GM111514 (HZ), R33CA186790 (HZ), U54 HG006434 (HZ), U24 CA160036 (HZ), P01NS097206 (HS) and R35NS097370 (GM).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>JW, Conceptualization, Data curation, Software, Methodology, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>YS, Data curation</p></fn><fn fn-type="con" id="con3"><p>QS, Data curation</p></fn><fn fn-type="con" id="con4"><p>BT, Data curation</p></fn><fn fn-type="con" id="con5"><p>OO, Data curation</p></fn><fn fn-type="con" id="con6"><p>SL, Data curation</p></fn><fn fn-type="con" id="con7"><p>MY, Resources</p></fn><fn fn-type="con" id="con8"><p>G-lM, Funding acquisition</p></fn><fn fn-type="con" id="con9"><p>HS, Resources, Funding acquisition</p></fn><fn fn-type="con" id="con10"><p>JQ, Conceptualization, Formal analysis, Supervision, Funding acquisition, Methodology, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con11"><p>HZ, Conceptualization, Formal analysis, Supervision, Funding acquisition, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con12"><p>SX, Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Methodology, Writing—original draft, Project administration, Writing—review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="SD5-data"><object-id pub-id-type="doi">10.7554/eLife.20068.019</object-id><label>Supplementary file 1.</label><caption><title>Direct downstream targets of KLF4-mCpG binding activity in GBM cells.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20068.019">http://dx.doi.org/10.7554/eLife.20068.019</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-20068-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="SD6-data"><object-id pub-id-type="doi">10.7554/eLife.20068.020</object-id><label>Supplementary file 2.</label><caption><title>Primer sequences used for bisulfite-PCR.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20068.020">http://dx.doi.org/10.7554/eLife.20068.020</ext-link></p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-20068-supp2-v2.docx"/></supplementary-material><sec id="s7" sec-type="datasets"><title>Major datasets</title><p>The following dataset was generated:</p><p><related-object content-type="generated-dataset" id="data-ro1" source-id="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97632" source-id-type="uri"><collab>Wan J</collab><x>,</x> <collab>Su Y</collab><x>,</x> <collab>Song Q</collab><x>,</x> <collab>Tung B</collab><x>,</x> <collab>Oyinlade O</collab><x>,</x> <collab>Liu S</collab><x>,</x> <collab>Ying M</collab><x>,</x> <collab>Ming G</collab><x>,</x> <collab>Song H</collab><x>,</x> <collab>Qian J</collab><x>,</x> <collab>Zhu H</collab><x>,</x> <collab>Xia S</collab><x>,</x> <year>2017</year><x>,</x><source>Methylation DNA mediated KLF4 binding activity in glioblastoma cells</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97632">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97632</ext-link><x>,</x> <comment>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE97632)</comment></related-object></p></sec></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashburner</surname><given-names>M</given-names></name><name><surname>Ball</surname><given-names>CA</given-names></name><name><surname>Blake</surname><given-names>JA</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name><name><surname>Butler</surname><given-names>H</given-names></name><name><surname>Cherry</surname><given-names>JM</given-names></name><name><surname>Davis</surname><given-names>AP</given-names></name><name><surname>Dolinski</surname><given-names>K</given-names></name><name><surname>Dwight</surname><given-names>SS</given-names></name><name><surname>Eppig</surname><given-names>JT</given-names></name><name><surname>Harris</surname><given-names>MA</given-names></name><name><surname>Hill</surname><given-names>DP</given-names></name><name><surname>Issel-Tarver</surname><given-names>L</given-names></name><name><surname>Kasarskis</surname><given-names>A</given-names></name><name><surname>Lewis</surname><given-names>S</given-names></name><name><surname>Matese</surname><given-names>JC</given-names></name><name><surname>Richardson</surname><given-names>JE</given-names></name><name><surname>Ringwald</surname><given-names>M</given-names></name><name><surname>Rubin</surname><given-names>GM</given-names></name><name><surname>Sherlock</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Gene Ontology: tool for the unification of biology. the Gene Ontology Consortium</article-title><source>Nature Genetics</source><volume>25</volume><fpage>25</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1038/75556</pub-id><pub-id pub-id-type="pmid">10802651</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>TL</given-names></name><name><surname>Elkan</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Fitting a mixture model by expectation maximization to discover motifs in biopolymers</article-title><source>Proceedings. International Conference on Intelligent Systems for Molecular Biology</source><volume>2</volume><fpage>28</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">7584402</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyes</surname><given-names>J</given-names></name><name><surname>Bird</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>DNA methylation inhibits transcription indirectly via a methyl-CpG binding protein</article-title><source>Cell</source><volume>64</volume><fpage>1123</fpage><lpage>1134</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(91)90267-3</pub-id><pub-id pub-id-type="pmid">2004419</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buganim</surname><given-names>Y</given-names></name><name><surname>Faddah</surname><given-names>DA</given-names></name><name><surname>Jaenisch</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mechanisms and models of somatic cell reprogramming</article-title><source>Nature Reviews Genetics</source><volume>14</volume><fpage>427</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1038/nrg3473</pub-id><pub-id pub-id-type="pmid">23681063</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlsson</surname><given-names>SK</given-names></name><name><surname>Brothers</surname><given-names>SP</given-names></name><name><surname>Wahlestedt</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Emerging treatment strategies for glioblastoma multiforme</article-title><source>EMBO Molecular Medicine</source><volume>6</volume><fpage>1359</fpage><lpage>1370</lpage><pub-id pub-id-type="doi">10.15252/emmm.201302627</pub-id><pub-id pub-id-type="pmid">25312641</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charlet</surname><given-names>J</given-names></name><name><surname>Duymich</surname><given-names>CE</given-names></name><name><surname>Lay</surname><given-names>FD</given-names></name><name><surname>Mundbjerg</surname><given-names>K</given-names></name><name><surname>Dalsgaard Sørensen</surname><given-names>K</given-names></name><name><surname>Liang</surname><given-names>G</given-names></name><name><surname>Jones</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Bivalent regions of Cytosine methylation and H3K27 acetylation suggest an active role for DNA methylation at enhancers</article-title><source>Molecular Cell</source><volume>62</volume><fpage>422</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2016.03.033</pub-id><pub-id pub-id-type="pmid">27153539</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>RZ</given-names></name><name><surname>Pettersson</surname><given-names>U</given-names></name><name><surname>Beard</surname><given-names>C</given-names></name><name><surname>Jackson-Grusby</surname><given-names>L</given-names></name><name><surname>Jaenisch</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>DNA hypomethylation leads to elevated mutation rates</article-title><source>Nature</source><volume>395</volume><fpage>89</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1038/25779</pub-id><pub-id pub-id-type="pmid">9738504</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christman</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy</article-title><source>Oncogene</source><volume>21</volume><fpage>5483</fpage><lpage>5495</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1205699</pub-id><pub-id pub-id-type="pmid">12154409</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cirillo</surname><given-names>LA</given-names></name><name><surname>Lin</surname><given-names>FR</given-names></name><name><surname>Cuesta</surname><given-names>I</given-names></name><name><surname>Friedman</surname><given-names>D</given-names></name><name><surname>Jarnik</surname><given-names>M</given-names></name><name><surname>Zaret</surname><given-names>KS</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4</article-title><source>Molecular Cell</source><volume>9</volume><fpage>279</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(02)00459-8</pub-id><pub-id pub-id-type="pmid">11864602</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drouin</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Minireview: pioneer transcription factors in cell fate specification</article-title><source>Molecular Endocrinology</source><volume>28</volume><fpage>989</fpage><lpage>998</lpage><pub-id pub-id-type="doi">10.1210/me.2014-1084</pub-id><pub-id pub-id-type="pmid">24825399</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elsir</surname><given-names>T</given-names></name><name><surname>Edqvist</surname><given-names>PH</given-names></name><name><surname>Carlson</surname><given-names>J</given-names></name><name><surname>Ribom</surname><given-names>D</given-names></name><name><surname>Bergqvist</surname><given-names>M</given-names></name><name><surname>Ekman</surname><given-names>S</given-names></name><name><surname>Popova</surname><given-names>SN</given-names></name><name><surname>Alafuzoff</surname><given-names>I</given-names></name><name><surname>Ponten</surname><given-names>F</given-names></name><name><surname>Nistér</surname><given-names>M</given-names></name><name><surname>Smits</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A study of embryonic stem cell-related proteins in human astrocytomas: identification of Nanog as a predictor of survival</article-title><source>International Journal of Cancer</source><volume>134</volume><fpage>1123</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1002/ijc.28441</pub-id><pub-id pub-id-type="pmid">24037901</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>PM</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Roles of Krüpel-like factor 4 in normal homeostasis, Cancer and stem cells</article-title><source>Acta Biochimica Et Biophysica Sinica</source><volume>40</volume><fpage>554</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1111/j.1745-7270.2008.00439.x</pub-id><pub-id pub-id-type="pmid">18604447</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feinberg</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Phenotypic plasticity and the epigenetics of human disease</article-title><source>Nature</source><volume>447</volume><fpage>433</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1038/nature05919</pub-id><pub-id pub-id-type="pmid">17522677</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feinberg</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>DNA methylation in Cancer: three decades of discovery</article-title><source>Genome Medicine</source><volume>6</volume><elocation-id>36</elocation-id><pub-id pub-id-type="doi">10.1186/gm553</pub-id><pub-id pub-id-type="pmid">25031622</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldmann</surname><given-names>A</given-names></name><name><surname>Ivanek</surname><given-names>R</given-names></name><name><surname>Murr</surname><given-names>R</given-names></name><name><surname>Gaidatzis</surname><given-names>D</given-names></name><name><surname>Burger</surname><given-names>L</given-names></name><name><surname>Schübeler</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Transcription factor occupancy can mediate active turnover of DNA methylation at regulatory regions</article-title><source>PLoS Genetics</source><volume>9</volume><elocation-id>e1003994</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1003994</pub-id><pub-id pub-id-type="pmid">24367273</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filion</surname><given-names>GJ</given-names></name><name><surname>Zhenilo</surname><given-names>S</given-names></name><name><surname>Salozhin</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>D</given-names></name><name><surname>Prokhortchouk</surname><given-names>E</given-names></name><name><surname>Defossez</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A family of human zinc finger proteins that bind methylated DNA and repress transcription</article-title><source>Molecular and Cellular Biology</source><volume>26</volume><fpage>169</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1128/MCB.26.1.169-181.2006</pub-id><pub-id pub-id-type="pmid">16354688</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>T</given-names></name><name><surname>He</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Tan</surname><given-names>K</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>EnhancerAtlas: a resource for enhancer annotation and analysis in 105 human cell/tissue types</article-title><source>Bioinformatics</source><volume>32</volume><fpage>3543</fpage><lpage>3551</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btw495</pub-id><pub-id pub-id-type="pmid">27515742</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>CR</given-names></name><name><surname>Lal</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Ho</surname><given-names>S</given-names></name><name><surname>Xia</surname><given-names>S</given-names></name><name><surname>Taeger</surname><given-names>A</given-names></name><name><surname>Murray</surname><given-names>J</given-names></name><name><surname>Laterra</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and akt activation</article-title><source>Cancer Research</source><volume>70</volume><fpage>2932</fpage><lpage>2941</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-3570</pub-id><pub-id pub-id-type="pmid">20233866</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawkins</surname><given-names>RD</given-names></name><name><surname>Hon</surname><given-names>GC</given-names></name><name><surname>Lee</surname><given-names>LK</given-names></name><name><surname>Ngo</surname><given-names>Q</given-names></name><name><surname>Lister</surname><given-names>R</given-names></name><name><surname>Pelizzola</surname><given-names>M</given-names></name><name><surname>Edsall</surname><given-names>LE</given-names></name><name><surname>Kuan</surname><given-names>S</given-names></name><name><surname>Luu</surname><given-names>Y</given-names></name><name><surname>Klugman</surname><given-names>S</given-names></name><name><surname>Antosiewicz-Bourget</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Espinoza</surname><given-names>C</given-names></name><name><surname>Agarwahl</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Ruotti</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Stewart</surname><given-names>R</given-names></name><name><surname>Thomson</surname><given-names>JA</given-names></name><name><surname>Ecker</surname><given-names>JR</given-names></name><name><surname>Ren</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Distinct epigenomic landscapes of pluripotent and lineage-committed human cells</article-title><source>Cell Stem Cell</source><volume>6</volume><fpage>479</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2010.03.018</pub-id><pub-id pub-id-type="pmid">20452322</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Teng</surname><given-names>L</given-names></name><name><surname>Tan</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Global view of enhancer-promoter interactome in human cells</article-title><source>PNAS</source><volume>111</volume><fpage>E2191</fpage><lpage>E2199</lpage><pub-id pub-id-type="doi">10.1073/pnas.1320308111</pub-id><pub-id pub-id-type="pmid">24821768</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmberg</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Peredo</surname><given-names>I</given-names></name><name><surname>Orrego</surname><given-names>A</given-names></name><name><surname>Hesselager</surname><given-names>G</given-names></name><name><surname>Ericsson</surname><given-names>C</given-names></name><name><surname>Hovatta</surname><given-names>O</given-names></name><name><surname>Oba-Shinjo</surname><given-names>SM</given-names></name><name><surname>Marie</surname><given-names>SK</given-names></name><name><surname>Nistér</surname><given-names>M</given-names></name><name><surname>Muhr</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Activation of neural and pluripotent stem cell signatures correlates with increased malignancy in human glioma</article-title><source>PLoS One</source><volume>6</volume><fpage>e18454</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0018454</pub-id><pub-id pub-id-type="pmid">21483788</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Q</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Aronow</surname><given-names>BJ</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>LMO7 mediates cell-specific activation of the Rho-myocardin-related transcription factor-serum response factor pathway and plays an important role in breast Cancer cell migration</article-title><source>Molecular and Cellular Biology</source><volume>31</volume><fpage>3223</fpage><lpage>3240</lpage><pub-id pub-id-type="doi">10.1128/MCB.01365-10</pub-id><pub-id pub-id-type="pmid">21670154</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Wan</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>Q</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Nguyen</surname><given-names>HN</given-names></name><name><surname>Shin</surname><given-names>J</given-names></name><name><surname>Cox</surname><given-names>E</given-names></name><name><surname>Rho</surname><given-names>HS</given-names></name><name><surname>Woodard</surname><given-names>C</given-names></name><name><surname>Xia</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Lyu</surname><given-names>H</given-names></name><name><surname>Ming</surname><given-names>GL</given-names></name><name><surname>Wade</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>DNA methylation presents distinct binding sites for human transcription factors</article-title><source>eLife</source><volume>2</volume><elocation-id>e00726</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.00726</pub-id><pub-id pub-id-type="pmid">24015356</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwafuchi-Doi</surname><given-names>M</given-names></name><name><surname>Zaret</surname><given-names>KS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Pioneer transcription factors in cell reprogramming</article-title><source>Genes &amp; Development</source><volume>28</volume><fpage>2679</fpage><lpage>2692</lpage><pub-id pub-id-type="doi">10.1101/gad.253443.114</pub-id><pub-id pub-id-type="pmid">25512556</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaenisch</surname><given-names>R</given-names></name><name><surname>Bird</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals</article-title><source>Nature Genetics</source><volume>33 Suppl</volume><fpage>245</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1038/ng1089</pub-id><pub-id pub-id-type="pmid">12610534</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlsson</surname><given-names>R</given-names></name><name><surname>Pedersen</surname><given-names>ED</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Brakebusch</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Rho GTPase function in tumorigenesis</article-title><source>Biochimica Et Biophysica Acta (BBA) - Reviews on Cancer</source><volume>1796</volume><fpage>91</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.bbcan.2009.03.003</pub-id><pub-id pub-id-type="pmid">19327386</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krueger</surname><given-names>F</given-names></name><name><surname>Andrews</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications</article-title><source>Bioinformatics</source><volume>27</volume><fpage>1571</fpage><lpage>1572</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btr167</pub-id><pub-id pub-id-type="pmid">21493656</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leng</surname><given-names>Z</given-names></name><name><surname>Tao</surname><given-names>K</given-names></name><name><surname>Xia</surname><given-names>Q</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Yue</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Xi</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Krüppel-like factor 4 acts as an oncogene in Colon cancer stem cell-enriched spheroid cells</article-title><source>PLoS One</source><volume>8</volume><elocation-id>e56082</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0056082</pub-id><pub-id pub-id-type="pmid">23418515</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Glas</surname><given-names>M</given-names></name><name><surname>Lal</surname><given-names>B</given-names></name><name><surname>Ying</surname><given-names>M</given-names></name><name><surname>Sang</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>S</given-names></name><name><surname>Trageser</surname><given-names>D</given-names></name><name><surname>Guerrero-Cázares</surname><given-names>H</given-names></name><name><surname>Eberhart</surname><given-names>CG</given-names></name><name><surname>Quiñones-Hinojosa</surname><given-names>A</given-names></name><name><surname>Scheffler</surname><given-names>B</given-names></name><name><surname>Laterra</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype</article-title><source>PNAS</source><volume>108</volume><fpage>9951</fpage><lpage>9956</lpage><pub-id pub-id-type="doi">10.1073/pnas.1016912108</pub-id><pub-id pub-id-type="pmid">21628563</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Olanrewaju</surname><given-names>YO</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Hashimoto</surname><given-names>H</given-names></name><name><surname>Blumenthal</surname><given-names>RM</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Structural basis for Klf4 recognition of methylated DNA</article-title><source>Nucleic Acids Research</source><volume>42</volume><fpage>4859</fpage><lpage>4867</lpage><pub-id pub-id-type="doi">10.1093/nar/gku134</pub-id><pub-id pub-id-type="pmid">24520114</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lupien</surname><given-names>M</given-names></name><name><surname>Eeckhoute</surname><given-names>J</given-names></name><name><surname>Meyer</surname><given-names>CA</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Carroll</surname><given-names>JS</given-names></name><name><surname>Liu</surname><given-names>XS</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription</article-title><source>Cell</source><volume>132</volume><fpage>958</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.01.018</pub-id><pub-id pub-id-type="pmid">18358809</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>IK</given-names></name><name><surname>Chatterjee</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Weirauch</surname><given-names>MT</given-names></name><name><surname>Hughes</surname><given-names>TR</given-names></name><name><surname>Vinson</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CG methylated microarrays identify a novel methylated sequence bound by the CEBPB|ATF4 heterodimer that is active in vivo</article-title><source>Genome Research</source><volume>23</volume><fpage>988</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1101/gr.146654.112</pub-id><pub-id pub-id-type="pmid">23590861</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nandan</surname><given-names>MO</given-names></name><name><surname>Yang</surname><given-names>VW</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The role of Krüppel-like factors in the reprogramming of somatic cells to induced pluripotent stem cells</article-title><source>Histology and Histopathology</source><volume>24</volume><fpage>1343</fpage><lpage>1355</lpage><pub-id pub-id-type="doi">10.14670/HH-24.1343</pub-id><pub-id pub-id-type="pmid">19688699</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narumiya</surname><given-names>S</given-names></name><name><surname>Tanji</surname><given-names>M</given-names></name><name><surname>Ishizaki</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion</article-title><source>Cancer and Metastasis Reviews</source><volume>28</volume><fpage>65</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1007/s10555-008-9170-7</pub-id><pub-id pub-id-type="pmid">19160018</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quick</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>D</given-names></name><name><surname>Hadziahmetovic</surname><given-names>M</given-names></name><name><surname>Chakravarti</surname><given-names>A</given-names></name><name><surname>Mehta</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Current therapeutic paradigms in glioblastoma</article-title><source>Reviews on Recent Clinical Trials</source><volume>5</volume><fpage>14</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.2174/157488710790820544</pub-id><pub-id pub-id-type="pmid">20205684</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reznik</surname><given-names>TE</given-names></name><name><surname>Sang</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Abounader</surname><given-names>R</given-names></name><name><surname>Rosen</surname><given-names>EM</given-names></name><name><surname>Xia</surname><given-names>S</given-names></name><name><surname>Laterra</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor</article-title><source>Molecular Cancer Research</source><volume>6</volume><fpage>139</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-07-0236</pub-id><pub-id pub-id-type="pmid">18234969</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rishi</surname><given-names>V</given-names></name><name><surname>Bhattacharya</surname><given-names>P</given-names></name><name><surname>Chatterjee</surname><given-names>R</given-names></name><name><surname>Rozenberg</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Glass</surname><given-names>K</given-names></name><name><surname>Fitzgerald</surname><given-names>P</given-names></name><name><surname>Vinson</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>CpG methylation of half-CRE sequences creates C/EBPalpha binding sites that activate some tissue-specific genes</article-title><source>PNAS</source><volume>107</volume><fpage>20311</fpage><lpage>20316</lpage><pub-id pub-id-type="doi">10.1073/pnas.1008688107</pub-id><pub-id pub-id-type="pmid">21059933</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowland</surname><given-names>BD</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name><name><surname>Peeper</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene</article-title><source>Nature Cell Biology</source><volume>7</volume><fpage>1074</fpage><lpage>1082</lpage><pub-id pub-id-type="doi">10.1038/ncb1314</pub-id><pub-id pub-id-type="pmid">16244670</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasai</surname><given-names>N</given-names></name><name><surname>Nakao</surname><given-names>M</given-names></name><name><surname>Defossez</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Sequence-specific recognition of methylated DNA by human zinc-finger proteins</article-title><source>Nucleic Acids Research</source><volume>38</volume><fpage>5015</fpage><lpage>5022</lpage><pub-id pub-id-type="doi">10.1093/nar/gkq280</pub-id><pub-id pub-id-type="pmid">20403812</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serra</surname><given-names>RW</given-names></name><name><surname>Fang</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>SM</given-names></name><name><surname>Hutchinson</surname><given-names>L</given-names></name><name><surname>Green</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype</article-title><source>eLife</source><volume>3</volume><elocation-id>e02313</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.02313</pub-id><pub-id pub-id-type="pmid">24623306</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Kelly</surname><given-names>TK</given-names></name><name><surname>Jones</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Epigenetics in cancer</article-title><source>Carcinogenesis</source><volume>31</volume><fpage>27</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgp220</pub-id><pub-id pub-id-type="pmid">19752007</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spruijt</surname><given-names>CG</given-names></name><name><surname>Gnerlich</surname><given-names>F</given-names></name><name><surname>Smits</surname><given-names>AH</given-names></name><name><surname>Pfaffeneder</surname><given-names>T</given-names></name><name><surname>Jansen</surname><given-names>PW</given-names></name><name><surname>Bauer</surname><given-names>C</given-names></name><name><surname>Münzel</surname><given-names>M</given-names></name><name><surname>Wagner</surname><given-names>M</given-names></name><name><surname>Müller</surname><given-names>M</given-names></name><name><surname>Khan</surname><given-names>F</given-names></name><name><surname>Eberl</surname><given-names>HC</given-names></name><name><surname>Mensinga</surname><given-names>A</given-names></name><name><surname>Brinkman</surname><given-names>AB</given-names></name><name><surname>Lephikov</surname><given-names>K</given-names></name><name><surname>Müller</surname><given-names>U</given-names></name><name><surname>Walter</surname><given-names>J</given-names></name><name><surname>Boelens</surname><given-names>R</given-names></name><name><surname>van Ingen</surname><given-names>H</given-names></name><name><surname>Leonhardt</surname><given-names>H</given-names></name><name><surname>Carell</surname><given-names>T</given-names></name><name><surname>Vermeulen</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives</article-title><source>Cell</source><volume>152</volume><fpage>1146</fpage><lpage>1159</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.02.004</pub-id><pub-id pub-id-type="pmid">23434322</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>YG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Tet family proteins and 5-hydroxymethylcytosine in development and disease</article-title><source>Development</source><volume>139</volume><fpage>1895</fpage><lpage>1902</lpage><pub-id pub-id-type="doi">10.1242/dev.070771</pub-id><pub-id pub-id-type="pmid">22569552</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tetreault</surname><given-names>MP</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Katz</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Krüppel-like factors in Cancer</article-title><source>Nature Reviews Cancer</source><volume>13</volume><fpage>701</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1038/nrc3582</pub-id><pub-id pub-id-type="pmid">24060862</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Papadopoulos</surname><given-names>N</given-names></name><name><surname>Velculescu</surname><given-names>VE</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Diaz</surname><given-names>LA</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cancer genome landscapes</article-title><source>Science</source><volume>339</volume><fpage>1546</fpage><lpage>1558</lpage><pub-id pub-id-type="doi">10.1126/science.1235122</pub-id><pub-id pub-id-type="pmid">23539594</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>SD</given-names></name><name><surname>Rath</surname><given-names>P</given-names></name><name><surname>Lal</surname><given-names>B</given-names></name><name><surname>Richard</surname><given-names>JP</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Goodwin</surname><given-names>CR</given-names></name><name><surname>Laterra</surname><given-names>J</given-names></name><name><surname>Xia</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase</article-title><source>Oncogene</source><volume>31</volume><fpage>5132</fpage><lpage>5143</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.16</pub-id><pub-id pub-id-type="pmid">22310282</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>S</given-names></name><name><surname>Rosen</surname><given-names>EM</given-names></name><name><surname>Laterra</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Sensitization of glioma cells to Fas-dependent apoptosis by chemotherapy-induced oxidative stress</article-title><source>Cancer Research</source><volume>65</volume><fpage>5248</fpage><lpage>5255</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-4332</pub-id><pub-id pub-id-type="pmid">15958570</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ying</surname> <given-names>M</given-names></name><name><surname>Sang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Guerrero-Cazares</surname><given-names>H</given-names></name><name><surname>Quinones-Hinojosa</surname><given-names>A</given-names></name><name><surname>Vescovi</surname><given-names>AL</given-names></name><name><surname>Eberhart</surname><given-names>CG</given-names></name><name><surname>Xia</surname><given-names>S</given-names></name><name><surname>Laterra</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011a</year><article-title>Krüppel-like family of transcription factor 9, a differentiation-associated transcription factor, suppresses Notch1 signaling and inhibits glioblastoma-initiating stem cells</article-title><source>Stem Cells</source><volume>29</volume><fpage>20</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1002/stem.561</pub-id><pub-id pub-id-type="pmid">21280156</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ying</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Sang</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>P</given-names></name><name><surname>Lal</surname><given-names>B</given-names></name><name><surname>Goodwin</surname><given-names>CR</given-names></name><name><surname>Guerrero-Cazares</surname><given-names>H</given-names></name><name><surname>Quinones-Hinojosa</surname><given-names>A</given-names></name><name><surname>Laterra</surname><given-names>J</given-names></name><name><surname>Xia</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011b</year><article-title>Regulation of glioblastoma stem cells by retinoic acid: role for notch pathway inhibition</article-title><source>Oncogene</source><volume>30</volume><fpage>3454</fpage><lpage>3467</lpage><pub-id pub-id-type="doi">10.1038/onc.2011.58</pub-id><pub-id pub-id-type="pmid">21383690</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Ray</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Ai</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Kruppel-like factor 4 (KLF4) is required for maintenance of breast Cancer stem cells and for cell migration and invasion</article-title><source>Oncogene</source><volume>30</volume><fpage>2161</fpage><lpage>2172</lpage><pub-id pub-id-type="doi">10.1038/onc.2010.591</pub-id><pub-id pub-id-type="pmid">21242971</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Transcription factors as readers and effectors of DNA methylation</article-title><source>Nature Reviews Genetics</source><volume>17</volume><fpage>551</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1038/nrg.2016.83</pub-id><pub-id pub-id-type="pmid">27479905</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>XY</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Luan</surname><given-names>SH</given-names></name><name><surname>Zhang</surname><given-names>HS</given-names></name><name><surname>Huang</surname><given-names>WT</given-names></name><name><surname>Wang</surname><given-names>NH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The PGI-KLF4 pathway regulates self-renewal of glioma stem cells residing in the mesenchymal niches in human gliomas</article-title><source>Neoplasma</source><volume>61</volume><fpage>401</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.4149/neo_2014_049</pub-id><pub-id pub-id-type="pmid">24645841</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.20068.023</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ren</surname><given-names>Bing</given-names></name><role>Reviewing editor</role><aff><institution>University of California, San Diego School of Medicine</institution>, <country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;Methylated cis-regulatory elements mediate KLF4-dependent gene transactivation and cell migration&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, one of whom, Bing Ren (Reviewer #1), is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Kevin Struhl as the Senior Editor.</p><p>Your work has been considered by the editors and three reviewers. The comments from the reviewers are attached. The reviewers recognize the potential significance of your finding of the function of DNA methylation-dependent binding of Klf4 in cell adhesion and migration, but raised considerable concerns regarding experimental evidence and the conclusions. In light of these concerns we cannot recommend publication of this manuscript. However, if you are able to address fully the main concerns as listed below then we would be happy to consider a much-revised version of the manuscript.</p><p>Essential revisions:</p><p>1) New experimental evidence is required to fully establish the DNA methylation dependent binding of wild type and the mutant form. Control experiments with Klf4 mutant lacking DNA binding potential altogether needs to be conducted; DNA methylation and motif analysis of the cell systems need to be performed.</p><p>2) Causality of DNA methylation dependent binding of Klf4 on the genome and induction of some target genes needs to be more fully established. As pointed by reviewer #3, the presence of the binding within 10kb of the promoter does not prove direct targeting relationship. New experimental data should be provided to support the notion that a target gene is directly regulated by Klf4's binding to the methylated DNA near the gene. This could be CRISPR/cas9 mediated genome editing or other means.</p><p>3) The treatment of cells by 5-Aza is inducing global DNA demethylation, and the observed phenotypes in the cell system can be attributed to non-specific effects. The authors need to discuss this aspect of the experiments to avoid drawing un-substantiated conclusions.</p><p>4) Statistical methods need to be better described and experimental data need to be more rigorously interpreted. Please check their comments carefully and make sure to remove or modify the particular statements in the revised manuscript.</p><p><italic>Reviewer #1</italic></p><p>In this manuscript Wan et al. reported the finding that Klf4 can indeed bind methylated DNA to activate transcription of genes in mammalian cells. Work in the laboratory of one of the co-authors (Dr. Zhu) previously showed that Klf4 could recognize DNA motifs with methylated CpG, and a point mutation R458A disrupts its methyl-DNA binding but not affect the binding to unmethylated sequences. In the current work, the authors tried to demonstrate function of the methyl-CG binding of Klf4. They chose two gliobastoma multiforme (GBM) cell lines U87 and U373 expressing either an inducible Wild Type Klf4 or one with R458A mutation. They found that upon induction of WT Klf4, but not MT form, the GBM cells acquire cell adhesion and migratory properties. They further investigated the binding sites of the two forms of proteins, and identified a substantial number of binding sites for the WT form but not the methyl-binding defective mutant. The also carried out RNA-seq analyses to identify genes regulated differentially by the WT versus Mutant form, and linked some of them to the differential binding of the Klf4 proteins. They claimed to identify 116 genes activated by mCpG-dependent KLF4 binding activity. In order to link the differential binding to DNA methylation at DNA, the group picked 15 regions and performed bisulfite sequencing. They showed that 10 of them contain DNA methylation. The authors conclude that Klf4's methyl-CG binding activity is critical for its role in mediating cell adhesion and migration in the GBM cells, and its binding to the methylated sites results in chromatin remodeling and transcription activation.</p><p>The work represents an in-depth follow up study of a phenomenon that some transcription factors binds to methylated DNA. The authors provided multiple lines of evidence supporting the functional role of methyl-CpG binding of Klf4. However, they also made some over-statement, and some conclusions are not sufficiently established with existing evidence. Additional experiments and analyses are needed to strengthen these conclusions.</p><p>Major problems:</p><p>1) Differential binding of WT and R458A Klf4 in GBM cells: Is this due to failure of the mutant protein to bind methylated DNA? Unfortunately, the evidence presented is weak: the authors performed Bisulfite Sequencing on 15 sites and found that 10 of them contain methylated CpG. Are these DNA sequences recognized by WT Klf4 but not mutant klf4? EMSA should be performed to establish this point. Further, 15 is too small a number to generalize to the rest of the differential binding sites. It is important to carry out base-resolution analysis of DNA methylation in these cells and determined if differential DNA binding by WT and R458A Klf4 in the GBM cells is indeed correlated with presence of DNA methylation at the Klf4 binding motifs in these regions.</p><p>2) The authors claimed that 116 genes are activated by mCpG-dependent KLF4 binding activity. Again, the evidence to support this claim is weak. Besides the reasons outlined in #1, there is also a need to establish the causality of KLF4 binding to methylated DNA in the cells and activation of these genes. Since the authors observed partial loss of cell adhesion and migration after 5-AZA treatment, it is important to show that the induction of these 116 genes is affected by 5-AZA in the direction that is consistent with their being targeted by Klf4.</p><p>3) The 5-AZA treatment leads to partial loss of migration of cells expressing WT Klf4. Is this due to DNA methylation dependent binding of Klf4? It is necessary to demonstrate loss of DNA methylation and loss of Klf4 binding at some sites after treatment.</p><p><italic>Reviewer #2:</italic></p><p>Binding of transcription factors to methylated regions of the genome to activate gene transcription is a new paradigm, and several studies have provided convincing evidence supporting this hypothesis. The manuscript by Wan et al., 'Methylated cis-regulatory elements mediate KLF4-dependent gene transactivation and cell migration' supports this hypothesis. In this study Wan et al. provides the best evidence of transcription factors binding to methylated DNA motifs and mediating gene activation. The experiments support their hypothesis convincingly and the manuscript describes it well. However, there are certain aspects that need to be addressed before it can be accepted.</p><p>Previously, the authors discovered that KLF4 can bind to methylated motifs and that a mutation in KLF4, (R458A) inhibited binding to methylated motifs but not unmethylated motifs (Hu et al., <italic>eLife</italic> 2013). They used this mutation as a negative control in the examination of KLF4 binding to methylated DNA sequences. However, in the present manuscript, they do not show that KLF4 R458A is able to activate unmethylated motifs in their genomic assays as they showed previously in transfection experiments. They need a negative control with no KLF4 function.</p><p>The authors make stable cell lines in human glioblastoma U87cells. They make doxycycline inducible cells and do cellular and genomic experiments to probe the function of KLF4 binding to methylated DNA. As already stated, they need a third cell with no KLF4 function, it can be the parental cells.</p><p>Major points:</p><p>1) The authors observe KLF4 ChIP-seq in WT and R458A transfected cells. There are some key aspects that need to be included. How many / percentage of canonical and methylated sites are specific or shared between WT and R458A cells. A representation of the motifs needs to be addressed. <xref ref-type="fig" rid="fig3">Figure 3E</xref>, the authors need to provide the input track to the screenshot; it seems to be the background is high. Some other similar screenshots of genes as supplementary figures will be useful. MACS 1.4 has been used to call peaks for KLF4 while again MACS2 has been used to call peaks while comparing with the acetyl mark. It would be better if the authors use the same pipeline to call peaks, as they are different. Why do the authors need to call a broad peak in this case?</p><p>2) The R458A mutant binds to ~1200 regions, the authors need to provide details regarding these regions.</p><p>3) The methods do not indicate whether biological replicates were performed for the sequencing based assays, in that case reproducibility is questionable. The authors can also provide a supplementary summary table for the mapped reads for all the sequencing experiments.</p><p>4) <xref ref-type="fig" rid="fig1">Figure 1A</xref>: KLF4 expressed at a much higher level in the mutant version and can be observed consistently across the doses, still the authors find loss of physiological functions and KLF4 binding peaks needs explanation. The authors need to include a negative control or some KLF4 silencing assay to show WT KLF4 is directly correlated to the observed physiological changes such as cellular migration / wound healing / adhesion.</p><p>5) <xref ref-type="fig" rid="fig2">Figure 2B</xref>: Comparatively lesser focal location of F-actin and Vaculin can also be noted in R458A cells it will be helpful to if the authors show fields with similar number of cells as that of the WT cells.</p><p>6) <xref ref-type="fig" rid="fig5">Figure 5F</xref> subsection “KLF4-mCpG interactions activate RHOC via chromatin remodelling” It is evident treatment of WT cells with 5-aza and doxycycline induces expression of RHOC, so it is apparent expression of RHOC is not absolutely methylation / KLF4 dependent. The authors should explain this in their text. Authors should have R458A version of the figure.</p><p>7) What is the methylation status of the WT specific KLF4 chip peaks sharing acetylation mark.</p><p> <italic>Reviewer #3:</italic></p><p>The paper has a single major finding which is that the KLF4 R458 mutation, which presumably affects nothing other than binding to methylated DNA, is severely compromised in its ability to induce both cellular phenotypes and gene expression changes in GBM cell lines. Moreover, these changes induced by WT KLF4 are largely abrogated by removal of DNA methylation. If one assumes that R458 has no other role, and that methylation has no indirect impact on the effects of KLF4 binding, then the core findings do seem to be supported by several lines of evidence.</p><p>That said, the paper makes a series of claims that are not supported by the data, and contains interpretations that I believe are erroneous. It also seems to contain some redundancy. It strikes me that the paper would be stronger if most of the material presented was removed and only the essence was retained. I have grouped my major concerns into four points, some of which are applicable to multiple sections of the paper.</p><p>Major points:</p><p>1) The statistical analyses are incompletely described, interpreted incorrectly, confuse correlation with causality, and contain biases.</p><p>The RNA-seq, ChIP-seq, and bisulfite sections need to state which overlaps are significant, and what is the predictive power, otherwise there is a strong potential that the manuscript is mainly describing phenomena with little or no significant relationship, and/or is confusing weak correlations or random overlaps with causality, due to unwarranted conditioning on unproven expectation. This is relevant to several sections, starting with this one:</p><p>Subsection &quot;Identify direct targets of mCpG-dependent KLF4 interactions in GBM cells&quot; is flawed. 613 genes are identified as responsive to KLF4 overexpression (induced more than 2-fold). Then, &quot;To determine which genes were directly activated by mCpG-dependent KLF4 binding events, ChIP-seq identifies 3,890 peaks. 65 of these bind within 10kb of the promoter, or within the UTRs or exons of the induced genes, &quot;indicating that most likely they were direct targets of KLF4-mCpG interactions&quot; (this is the key point, so I quote from the text). I disagree that this shows that they are direct targets – the null hypothesis should be that there is no relationship, and in fact if there is any overlap it seems to be low. It is entirely possible that there is a random association between the ChIP data and the RNA-seq data, and even if it is nonrandom, the fold enrichment over random should be given.</p><p>Instead, this section concludes &quot;Taken together, a total of 116 genes were directly [my emphasis] up-regulated via mCpG-dependent KLF4 binding to the cis-regulatory elements in the proximal regulatory regions (56%) and distal enhancers (44%)&quot;. There is simply not the evidence in this paper to make that conclusion.</p><p>Since we don't have the right numbers in the current paper I will explain why the reasoning is flawed using typical numbers seen in other studies (which seem to be similar here). Let's say that there are 10,000 active genes, peaks are found in 900, 600 are up-regulated, and 60 overlap. So, peaks are found in 9% of all promoters, but 10% of up-regulated promoters. 6% of genes are up-regulated, and 7% of genes with a peak are up-regulated. Certainly there is something statistically significant happening, but the relationship between binding sites and expression responses is weak, so even when we see it, we cannot infer causality. We know that many binding sites do nothing (at least 93%), and that many genes are induced with no binding at all (at least 90%). So, it is certainly possible that there could be genes that have a binding site that does nothing and are induced indirectly.</p><p>By analogy, if the same numbers were used for a high-cholesterol diet and heart attacks, we would be wrong to assume that all 60 people with heart attacks and a high cholesterol diet were caused by the diet, since certainly the diet is not deterministic, and there are multiple causes of heart attacks. Instead, we can conclude that seven of the heart attacks can be attributed to the diet, but we can't tell which seven they were.</p><p>In addition, two technical modifications of these analyses are needed to further avoid bias. First, the comparisons among binding sites, induced genes, marks etc need to be restricted to genes that are expressed at all in these cells – it is possible to get high overlaps among unrelated regulators only because everything tends to pile up on open chromatin and active promoters. Similarly, the GO analyses later in the paper should be done taking the induced genes as a background. KLF4 overexpression induces migration and morphological changes, which could explain why genes related to this process are expressed. It is possible that KLF4 only directly induces a small number of genes, and the rest of what we are seeing is a secondary effect.</p><p><italic>eLife</italic> asked me to write a short review, but the same issues pervade subsequent analyses of overlaps with histone ChIP data and methylation. It is abundantly clear from ENCODE that there are lots of pervasive marks of all kinds in all cell types, many of which concentrate in active regions. Not every overlap is functionally significant, however, and in fact it is likely that most of them are doing nothing at any given time.</p><p>2) It seems possible that global DNA demethylation could attenuate the ability of cells to do many things, and thus the results shown in <xref ref-type="fig" rid="fig2">Figure 2C and D</xref> could be nonspecific. Are there other perturbations that can trigger the same responses that are being assayed, and are these responses intact in aza-treated cells? If not, then the effects cannot really be attributed to a specific effect of KLF4 binding.</p><p>3) I do not see that <xref ref-type="fig" rid="fig5">Figure 5</xref> adds anything to the paper. It is simply a reiteration of assays already used earlier on a global scale, but using PCR assays. The same issues I describe above in major points 1 and 2 also apply to these results – I believe that the final statement &quot;Therefore, high methylation level in RHOC promoter is essential for KLF4 WT to activate RHOC transcription&quot; is rather an overstatement. The first sentence is better supported: &quot;Several lines of evidence supported that DNA methylation mediated RHOC activation by KLF4 WT&quot;. On the whole, however, this is the same argument that has already been made in genome-wide analyses, with no new evidence. I would suggest that this section is dispensible, since it only confirms what would be expected from the rest of the manuscript.</p><p>4) The association of active marks with induced promoters and with many of the Klf4 sites is unsurprising – this would be seen even if the induction of the supposed &quot;target genes&quot; was indirect, and the KLF4 binding was coincidental. Indeed, the fact that there are 3,593 novel H3K27ac peaks, but only 274 overlap KLF4, shows that the two are largely dissociated. Thus, the statement in the Discussion that &quot;Our study reveals that mCpG-dependent binding activity of KLF4 serves as the link between methylated CpG and changes in chromatin status&quot; is not supported by the data shown. It is &quot;a&quot; link, but not &quot;the&quot; link.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.20068.024</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>Essential revisions:</italic> </p><p> <italic>1) New experimental evidence is required to fully establish the DNA methylation dependent binding of wild type and the mutant form. Control experiments with Klf4 mutant lacking DNA binding potential altogether needs to be conducted; DNA methylation and motif analysis of the cell systems need to be performed.</italic> </p><p>To fully examine the DNA methylation status of KLF4 WT and R458A ChIP-seq peaks, we performed whole genome bisulfite sequencing to decode the methylome of U87 cells and combined the DNA methylome data separately with the KLF4 WT and R458A ChIP-seq datasets. We found that 66% of the KLF4 WT-specific ChIP-seq peaks showed a high methylation level (e.g., β &gt; 60%) at CpG sites, while only 36% of the ChIP-seq peaks shared by KLF4 WT and R458A reached a similar CpG methylation level (<italic>p</italic> = 3.7e-223). Different cutoffs for defining high methylation levels did not alter this observation (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Therefore, the KLF4 WT-specific ChIP peaks are enriched for highly methylated CpGs. In the revised manuscript, we have incorporated the new data in <xref ref-type="fig" rid="fig3">Figure 3F</xref>.</p><p>Next, we carried out motif analysis to identify enriched and highly methylated 6-mer DNA motifs in WT-specific ChIP-seq peaks, as well as in shared ChIP-seq peaks. At a cutoff of β &gt; 60% CpG methylation we found 10 methylated 6-mer motifs that were significantly over-represented in the WT-specific peaks (<italic>p</italic> = 6.6e-37). Many of them share sequence similarity to the motif 5’-CCCGCC (<xref ref-type="fig" rid="fig3">Figure 3G</xref>, of which the methylated form was reported to be recognized by KLF4 in our previous study (Hu et al., <italic>eLife</italic> 2013). In contrast, the peaks shared by WT and R458A were found to be enriched for different motifs (e.g., 5’-AAAAGGAA and 5’- GAGTTGAA). The new data is now in <xref ref-type="fig" rid="fig3">Figure 3G</xref>. Taken together, these new data confirmed that the KLF4 WT-specific ChIP-seq peaks were enriched for highly methylated KLF4 binding motifs.</p><p>We respectfully disagree that “control experiments with Klf4 mutant lacking DNA binding potential altogether needs to be conducted” because it would not further strengthen the conclusion of this study. In a previous study, the Goldberg group nicely showed that induction of a <italic>KLF4ΔC</italic> (lacking the entire KLF4 DNA binding domain) in mouse retinal ganglion cells could no longer suppress the axon outgrowth as the WT did (Moore et al., <italic>Science</italic> 2009 326(5950):298-301). Similarly, induction of the <italic>R458A</italic> mutant on the same background showed the same phenotype as <italic>KLF4ΔC</italic> (Goldberg; personal communication), suggesting the removal of the entire DNA binding domain of KLF4 did not cause any additional phenotype. Even if a truncated KLF4 mutant might cause additional phenotypes, it is not the focus of this study. In our opinion, the R458A mutant is the most relevant comparison with KLF4 WT because it loses the ability to bind to methylated DNA motifs while maintaining binding activity to KLF4’s canonical motif (Hu et al., <italic>eLife</italic> 2013). Using a truncated KLF4 mutant that lacks the entire DNA binding domains would not help us to identify mCpG-dependent KLF4 targets because we would not be able to distinguish KLF4-mCpG binding from the canonical KLF4 binding activity.</p><p><italic>2) Causality of DNA methylation dependent binding of Klf4 on the genome and induction of some target genes needs to be more fully established. As pointed by reviewer #3, the presence of the binding within 10kb of the promoter does not prove direct targeting relationship. New experimental data should be provided to support the notion that a target gene is directly regulated by Klf4's binding to the methylated DNA near the gene. This could be CRISPR/cas9 mediated genome editing or other means.</italic> </p><p>We thank the reviewers for this constructive suggestion. On the basis of the reviewers’ suggestion, we selected two genes, namely <italic>RAC1</italic> and <italic>RHOC</italic>, because 1) they are known to play a crucial role in cell migration; 2) we found that they were associated with WT-specific ChIP-seq peaks and genome-wide bisulfite sequencing confirmed that these peaks contained highly methylated CpGs; and 3) these peaks are in close proximity to the coding regions of <italic>RAC1</italic> (-922 bp to TSS) and <italic>RHOC</italic> (-507bp to TSS). In a newly added case of <italic>RAC1</italic>, we first showed that induction of KLF4 WT, but not the R458A mutant, induced <italic>RAC1</italic> expression at both mRNA and protein levels using RT-PCR and immunoblot analysis, respectively (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A and B</xref>). Using a primer pair flanking <italic>RAC1</italic> ChIP-seq peak, we confirmed that this fragment could be ChIPed substantially better with the KLF4 WT than the R458A mutant (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref> C). To further establish the causality of DNA methylation-dependent binding of KLF4 on induction of its target genes, we performed bisulfite sequencing against this <italic>cis</italic>-regulatory element with and without the 5-Aza treatment. We observed that the methylation level of four of the six CpGs was reduced from ~100% to an undetectable level after 5-Aza treatment (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>). Most importantly, removal of methylation almost completely abolished KLF4 WT binding to this <italic>cis</italic>-regulatory element (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref>), and expression of <italic>RAC1</italic> was also significantly repressed (<italic>p</italic> &lt; 0.001; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1F</xref>).</p><p>In the case of <italic>RHOC</italic>, we carried out additional assays to further establish the causal relationship. We performed ChIP-PCR against its <italic>cis</italic>-regulatory element (-507 bp to TSS) with and without 5-Aza treatment and observed that reduction of methylation in this region also substantially reduced recruitment of KLF4 WT. Taken together, these new results demonstrate that KLF4 WT activated the expression of these two genes via binding to their highly methylated <italic>cis</italic>-regulatory elements nearby the coding regions. The new data is added as panel <xref ref-type="fig" rid="fig5">Figure 5E</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>).</p><p>To examine the impact of DNA demethylation on the global expression level, we performed RNA-seq analysis and compared changes in gene expression profiles with and without 5-Aza treatment. We observed that in the absence of KLF4 WT induction the overall expression levels of the 116 KLF4 WT-specific target genes were not significantly affected by 5-Aza treatment (<xref ref-type="fig" rid="fig4">Figure 4</xref>), as expected. However, when KLF4 WT was induced, the expression level of 101 of the 116 genes was reduced in 5-Aza treated cells as compared with untreated cells (Figure R4, right panel; <italic>p</italic> = 1.2e-14 compared to all expressed genes), suggesting that DNA methylation is responsible for the transcription activation of these 101 genes. The new data is in <xref ref-type="fig" rid="fig4">Figure 4F and G</xref>.</p><p>In our opinion, using CRISPR/Cas9-mediated genome editing may not help strengthen the causality because the mCpG-dependent KLF4 DNA binding activity is also sequence-specific (Hu et al., <italic>eLife</italic> 2013). In other words, the use of CRISPR/Cas9 to mutate the DNA sequence (i.e., CpG sites) of interest would not assist us to de-couple the effects of DNA sequence and DNA methylation on the KLF4 binding activity. Ideally, a CRISPR-guided site-specific DNA demethylation approach would be appropriate; however, this method might not guarantee maintenance of low DNA methylation level due to the endogenous DNA methyltransferase activity.</p><p> <italic>3) The treatment of cells by 5-Aza is inducing global DNA demethylation, and the observed phenotypes in the cell system can be attributed to non-specific effects. The authors need to discuss this aspect of the experiments to avoid drawing un-substantiated conclusions.</italic> </p><p>We agree with the reviewers and have added the following discussion to address this concern in Discussion section.</p><p>“We are fully aware that 5-Aza is only a sub-optimal approach to examine the effect of specific methylation sites, because it induces global demethylation and may have some non-specific effects (Christman et al., 2002). However, we have multiple lines of evidence showing that the observed phenotypes are due to specific interactions between KLF4 and methylated sites. (1) In our control experiments when KLF4 R458A cells were treated with 5-Aza, we did not see changes in gene expression and cell migration. (2) In the focused studies of <italic>RHOC</italic> and <italic>RAC1</italic>, we showed that DNA methylation is responsible for KLF4 binding and gene activation. <italic>RHOC</italic> and <italic>RAC1</italic> are major GTPase involved in cell migration and motility. (3) Comparison of ChIP-seq between KLF4 WT and R458A showed that WT-specific binding sites are enriched for highly methylated sites. Given the phenotypic differences between KLF4 WT and R458A, the result suggested that the observed phenotypes in WT are likely due to specific interactions between KLF4 and DNA methylation sites. (4) Our new RNA-seq data in the presence of 5-Aza also indicated that 5-Aza globally reversed the up-regulation of many KLF4-mCpG targets.”</p><p> <italic>4) Statistical methods need to be better described and experimental data need to be more rigorously interpreted. Please check their comments carefully and make sure to remove or modify the particular statements in the revised manuscript.</italic> </p><p>We thank reviewers for the constructive suggestion on the statistics analyses. We have added more rigorous statistical analyses throughout the revised manuscript according to the reviewers’ suggestions. Detailed responses can be found in the specific points raised by each reviewer. Please refer to our responses to reviewer #1’s major points 1 and 2; reviewer #2’s major points 1, 2, 3 and 7; reviewer #3’s major points 1 and 2. All of these new analyses have been incorporated into the revised manuscript.</p><p> <italic>Reviewer #1</italic></p><p><italic>[…] Major problems:</italic> </p><p> <italic>1) Differential binding of WT and R458A Klf4 in GBM cells: Is this due to failure of the mutant protein to bind methylated DNA? Unfortunately, the evidence presented is weak: the authors performed Bisulfite Sequencing on 15 sites and found that 10 of them contain methylated CpG. Are these DNA sequences recognized by WT Klf4 but not mutant klf4? EMSA should be performed to establish this point. Further, 15 is too small a number to generalize to the rest of the differential binding sites. It is important to carry out base-resolution analysis of DNA methylation in these cells and determined if differential DNA binding by WT and R458A Klf4 in the GBM cells is indeed correlated with presence of DNA methylation at the Klf4 binding motifs in these regions.</italic> </p><p>We appreciate the reviewer’s insightful suggestion. We have performed the whole genome bisulfite sequencing in GBM cells and combined this new dataset with KLF4 WT and R458A mutant ChIP-seq datasets. Please see our responses to essential revision #1 and #2 above for more details. Here are some highlights that are relevant to answer the reviewer’s questions: 1) WT-specific ChIP-seq peaks contained CpGs of a much higher methylation level than those peaks shared by the WT and R458A mutant (<xref ref-type="fig" rid="fig3">Figure 3</xref>) DNA motif analyses against those WT-specific peaks identified 10 significantly enriched motifs, all of which contained at least one CpG with significantly higher methylation level than those identified among the shared peaks (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). More importantly, in-depth in vivo studies demonstrated that removal of DNA methylation at the <italic>cis</italic>-regulatory elements in the promoters of two cell migration genes (<italic>RAC1</italic> and <italic>RHOC</italic>) abolished the recruitment of KLF4 WT to these promoters and repressed their gene transcription (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Taken together, these new results demonstrated that KLF4 WT activated the expression of these two genes via binding to their highly methylated <italic>cis</italic>-regulatory elements nearby the coding regions.</p><p> <italic>2) The authors claimed that 116 genes are activated by mCpG-dependent KLF4 binding activity. Again, the evidence to support this claim is weak. Besides the reasons outlined in #1, there is also a need to establish the causality of KLF4 binding to methylated DNA in the cells and activation of these genes. Since the authors observed partial loss of cell adhesion and migration after 5-AZA treatment, it is important to show that the induction of these 116 genes is affected by 5-AZA in the direction that is consistent with their being targeted by Klf4.</italic> </p><p>The reviewer suggested a very important way to strength our findings. Please see our responses to essential revision #2 above for more details. To examine the impact of demethylation on global expression level, we performed RNA-seq analysis and compared changes in gene expression profiles with and without 5-Aza treatment. We observed that in the absence of KLF4 WT induction the overall expression levels of the 116 KLF4 WT-specific target genes were not significantly affected by 5-Aza treatment (<xref ref-type="fig" rid="fig4">Figure 4</xref>), as expected. However, when KLF4 WT was induced, the expression levels of 101 of the 116 genes were significantly reduced in 5-Aza treated cells as compared with untreated cells (<xref ref-type="fig" rid="fig4">Figure 4B</xref> B, <italic>p</italic> = 1.2e-14 compared to all genes), suggesting that DNA methylation is responsible for the transcription activation of these 101 genes.</p><p> <italic>3) The 5-AZA treatment leads to partial loss of migration of cells expressing WT Klf4. Is this due to DNA methylation dependent binding of Klf4? It is necessary to demonstrate loss of DNA methylation and loss of Klf4 binding at some sites after treatment.</italic> </p><p>The answer is yes. Please see our response to essential revision #2.</p><p>On the basis of the reviewers’ suggestion, we selected two genes, namely <italic>RAC1</italic> and <italic>RHOC</italic>, because 1) they are known to play a crucial role in cell migration; 2) we found that they were associated with WT-specific ChIP-seq peaks and genome-wide bisulfite sequencing confirmed that these peaks contained highly methylated CpGs; and 3) these peaks are in close proximity to the coding regions of <italic>RAC1</italic> (-922 bp to TSS) and <italic>RHOC</italic> (-507 bp to TSS), respectively. In the case of <italic>RAC1</italic>, we first showed that induction of WT, but not the R458A mutant, could induce RAC1 at both mRNA and protein levels using RT-PCR and immunoblot analysis, respectively (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A and B</xref>). Using a primer pair flanking <italic>RAC1</italic> ChIP-seq peak, we confirmed that this fragment could be ChIPed substantially better with the KLF4 WT than the R458A mutant (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>). To further establish causality of DNA methylation-dependent binding of KLF4 on induction of its target genes, we performed bisulfite sequencing against this <italic>cis</italic>-regulatory element with and without the 5-Aza treatment. We observed that the methylation level of four of the six CpGs was reduced from ~100% to an undetectable level after 5-Aza treatment (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>). Most importantly, removal of methylation almost completely abolished KLF4 WT binding to this <italic>cis</italic>-regulatory element (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref>), and expression of <italic>RAC1</italic> was also significantly repressed (<italic>p</italic> &lt; 0.001; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1F</xref>). The same set of assays was also carried out to analyze the <italic>cis</italic>-regulatory elements of <italic>RHOC</italic> and the same results were obtained. Taken together, these new results demonstrated that KLF4 WT activated the expression of these two genes via binding to their highly methylated <italic>cis</italic>-regulatory elements nearby the coding regions.</p><p><italic>Reviewer #2:</italic> </p><p><italic>[…] Major points:</italic></p><p> <italic>1) The authors observe KLF4 ChIP-seq in WT and R458A transfected cells. There are some key aspects that need to be included. How many / percentage of canonical and methylated sites are specific or shared between WT and R458A cells. A representation of the motifs needs to be addressed. <xref ref-type="fig" rid="fig3">Figure 3E</xref>, the authors need to provide the input track to the screenshot; it seems to be the background is high. Some other similar screenshots of genes as supplementary figures will be useful. MACS 1.4 has been used to call peaks for KLF4 while again MACS2 has been used to call peaks while comparing with the acetyl mark. It would be better if the authors use the same pipeline to call peaks, as they are different. Why do the authors need to call a broad peak in this case?</italic> </p><p>We appreciate the reviewer’s positive comments and insightful suggestions to strengthen our findings. As discussed in essential point #1 above, we have performed the whole genome bisulfite sequencing and combined this dataset with our ChIP-seq datasets. We observed that 10 methylated 6-mer motifs, each containing one CpG of high methylation level (β&gt;0.6), were significantly enriched in the KLF4 WT-specific peaks, while distinct motifs without CpG sites were found enriched in the shared ChIP-seq peaks. Please see essential point #1 for more details.</p><p>We calculated numbers of WT-specific and shared peaks, respectively, including one of non-methylated motifs (5’-AAAGGA) and methylated (5’-CCCGCC) sites. We found that the non-methylated motif was significantly overrepresented in shared peaks (fold enrichment = 2.9, p = 7.7e-41), whereas the methylated motif was significantly enriched in WT-specific peaks (fold enrichment = 2.4, p = 3.0e-139).</p><p>We have also provided the input track and screenshot of some KLF4-mCpG target genes (see <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). The new data is now in <xref ref-type="fig" rid="fig3">Figure 3E</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B and C</xref>.</p><p>We agree that MACS2 is widely used for calling ChIP-seq peaks. In general, the results by MACS 1.4 were quite similar to those obtained using MACS2. However, in our case some peaks observed obvious to eye-balling (for example, the left one of twin peaks associated with RHOC in <xref ref-type="fig" rid="fig3">Figure 3E</xref>) could not be identified by MACS2. Therefore, we decided to use MACS1.4 for better sensitivity. For histone modifications in this paper, we used MACS2 to call broad peaks without any problem.</p><p> <italic>2) The R458A mutant binds to ~1200 regions, the authors need to provide details regarding these regions.</italic> </p><p>We now provide the chromosomal locations of the WT and R458A shared peaks listed in Figure 3—source data 33.</p><p> <italic>3) The methods do not indicate whether biological replicates were performed for the sequencing based assays, in that case reproducibility is questionable. The authors can also provide a supplementary summary table for the mapped reads for all the sequencing experiments.</italic> </p><p>We appreciate the reviewer’s comments. We have added the summary tables in <xref ref-type="supplementary-material" rid="SD1-data">Figure 3—source data 1</xref> and 2 for the mapped reads for all the sequencing experiments in our supplementary table and analyzed correlation of RNA-seq reads between the biological replicates. As showed in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>below, the reproducibility is very high (c.c. &gt; 0.8) between our two experiments. The new data is now in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>.</p><p> <italic>4) <xref ref-type="fig" rid="fig1">Figure 1A</xref>: KLF4 expressed at a much higher level in the mutant version and can be observed consistently across the doses, still the authors find loss of physiological functions and KLF4 binding peaks needs explanation. The authors need to include a negative control or some KLF4 silencing assay to show WT KLF4 is directly correlated to the observed physiological changes such as cellular migration / wound healing / adhesion.</italic> </p><p>We apologize for the poor explanation of the cell system we used in our study. The purpose of using tet-on system, i.e., doxycycline (Dox)-inducible cell lines for KLF4 functional study, was to have an internally-controlled system, such that when the cells are not treated with Dox, they behave like the parental cells, therefore serves as a control cell line to study the biological function of KLF4. Compared to their own control cells, the induction level of KLF4 R458A was a bit higher than that of KLF4 WT, consistent with as our more quantitative RNA-seq data indicating the fold change of KLF4 WT and KLF4 R458A are 20 and 27 fold, respectively. However, the differences in expression level did not affect the ability of KLF4’s binding to methylated CpGs, hence cellular phenotype changes. In the revised version, we specifically explained the tet-on cell system we used (<underline>Results section</underline>). Moreover, as the reviewer suggested, we did cell migration assays in the non-transfected U87 cells (control) and found that non-transfected U87 cells behave the same as the non-Dox treated U87 KLF4 WT cells. Please refer to our response to reviewer #2, major point 8 later.</p><p> <italic>5) <xref ref-type="fig" rid="fig2">Figure 2B</xref>: Comparatively lesser focal location of F-actin and Vaculin can also be noted in R458A cells it will be helpful to if the authors show fields with similar number of cells as that of the WT cells.</italic> </p><p>In the revised version, we have chosen more representative photographs to replace <xref ref-type="fig" rid="fig2">Figure 2B</xref>. These images support our conclusion that after Dox treatment KLF4 WT induced more focal locations as shown by F-actin and vinculin staining, and the cells were more spread out.</p><p> <italic>6) <xref ref-type="fig" rid="fig5">Figure 5F</xref> subsection “KLF4-mCpG interactions activate RHOC via chromatin remodelling” It is evident treatment of WT cells with 5-aza and doxycycline induces expression of RHOC, so it is apparent expression of RHOC is not absolutely methylation / KLF4 dependent. The authors should explain this in their text. Authors should have R458A version of the figure.</italic> </p><p>We redid the WB experiments together with KLF4 R458A mutant cells as the reviewer suggested. It showed that 5-Aza itself had minimal effect on the baseline expression of <italic>RHOC</italic> expression (<xref ref-type="fig" rid="fig5">Figure 5</xref>). In KLF4 WT cells, 5-Aza blocked <italic>RHOC</italic> upregulation induced by KLF4 WT. In KLF4 R458A cells, 5-Aza had no effect on <italic>RHOC</italic> expression under similar conditions. The data is now in <xref ref-type="fig" rid="fig5">Figure 5G</xref> in the revised manuscript.</p><p> <italic>7) What is the methylation status of the WT specific KLF4 chip peaks sharing acetylation mark.</italic> </p><p>The reviewer raised a very good point. Of 1,773 WT-specific KLF4 chip peaks sharing acetylation mark, 978 (55.2%) contain CpG sites of &gt;60% methylation level.</p><p> <italic>Reviewer #3:</italic> </p><p> <italic>[…] Major points:</italic> </p><p> <italic>1) […] In addition, two technical modifications of these analyses are needed to further avoid bias. First, the comparisons among binding sites, induced genes, marks etc need to be restricted to genes that are expressed at all in these cells – it is possible to get high overlaps among unrelated regulators only because everything tends to pile up on open chromatin and active promoters. Similarly, the GO analyses later in the paper should be done taking the induced genes as a background. KLF4 overexpression induces migration and morphological changes, which could explain why genes related to this process are expressed. It is possible that KLF4 only directly induces a small number of genes, and the rest of what we are seeing is a secondary effect.</italic> </p><p>We appreciate the points raised by the reviewer and performed additional statistical analyses according to the reviewer’s suggestions. We have calculated the statistical significance of the overlapped genes. We focused on 12,824 genes that were expressed (FPKM &gt; 0.5) in U87 cells. Among them, 308 (2.4%) up-regulated genes were identified. In the meantime, we observed that KLF4 mCpG-dependent binding peaks were associated with 1,072 expressed genes, of which 65 were up-regulated genes. The ratio of 6.1% is significantly higher than the ratio of expressed genes not associated with KLF4 binding sites (fold enrichment = 2.5; <italic>p</italic> = 1.2e-12). Adding KLF4 mCpG binding sites in enhancer region, we finally identified 116 targets out of 2,601 genes, indicating significantly over-representation (fold enrichment = 1.9; <italic>p</italic> = 5.0e-13). In the revised manuscript, we added this new analysis in the text (subsection “Identification of direct targets of mCpG-dependent KLF4 interactions in GBM cells”). In addition, we performed whole genome bisulfite sequencing, integrated it with the ChIP-seq datasets, and re-analyzed the data (see our response to essential point #1). We also obtained RNA-seq data after 5-Aza treatment and re-analyzed the entire dataset (see our response to essential point #2). To firmly establish the causality between mCpG-dependent KLF4 binding and target gene activation, we performed in-depth assays to examine impact of de-methylation on the recruitment of KLF4 WT to the promoter regions of two target genes in conjunction with changes in their RNA level (see our response to essential point #2).</p><p> <italic>2) It seems possible that global DNA demethylation could attenuate the ability of cells to do many things, and thus the results shown in <xref ref-type="fig" rid="fig2">Figure 2C and D</xref> could be nonspecific. Are there other perturbations that can trigger the same responses that are being assayed, and are these responses intact in aza-treated cells? If not, then the effects cannot really be attributed to a specific effect of KLF4 binding.</italic> </p><p><italic>Please see our response to essential point #3. As far as we know, 5-Aza treatment is the only effective means to reduce global DNA methylation level. In response to essential point #3, we have added discussion of 5-Aza treatment to the manuscript. To examine the impact of DNA demethylation on the global expression level, we performed RNA-seq analysis and compared changes in gene expression profiles with and without 5-Aza treatment. We observed that in the absence of KLF4 WT induction the overall expression levels of the 116 KLF4 WT-specific target genes were not significantly affected by 5-Aza treatment (see our response to essential point #2).</italic></p><p> <italic>3) I do not see that <xref ref-type="fig" rid="fig5">Figure 5</xref> adds anything to the paper. It is simply a reiteration of assays already used earlier on a global scale, but using PCR assays. The same issues I describe above in major points 1 and 2 also apply to these results – I believe that the final statement &quot;Therefore, high methylation level in RHOC promoter is essential for KLF4 WT to activate RHOC transcription&quot; is rather an overstatement. The first sentence is better supported: &quot;Several lines of evidence supported that DNA methylation mediated RHOC activation by KLF4 WT&quot;. On the whole, however, this is the same argument that has already been made in genome-wide analyses, with no new evidence. I would suggest that this section is dispensible, since it only confirms what would be expected from the rest of the manuscript.</italic> </p><p><italic>We respectfully disagree with the reviewer. <xref ref-type="fig" rid="fig5">Figure 5</xref> is not redundant because it serves four purposes. First, it addressed the causality issue raised in essential point #2. Second, focused studies are essential for rigorous validation of high throughput analyses, which often contains many false positives. Third, RHOC plays a crucial role in cell migration/adhesion pathways. The discovery that the gene was activated via mCpG-mediated KLF4 binding activity is significant and of great interest in cancer biology. Most importantly, results showed in <xref ref-type="fig" rid="fig5">Figure 5</xref> established a connection between dynamic changes of histone modifications and mCpG-dependent KLF4 binding activity in cells, which offered new molecular mechanism underlying mCpG-dependent gene activation. To address the concern of overstatement raised by the reviewer, we now offer more experimental and computational evidence as described in our responses to essential points #1 and #2. We believe that our in-depth study as illustrated in <xref ref-type="fig" rid="fig5">Figure 5</xref> is well justified.</italic></p><p> <italic>4) The association of active marks with induced promoters and with many of the Klf4 sites is unsurprising – this would be seen even if the induction of the supposed &quot;target genes&quot; was indirect, and the KLF4 binding was coincidental. Indeed, the fact that there are 3,593 novel H3K27ac peaks, but only 274 overlap KLF4, shows that the two are largely dissociated. Thus, the statement in the Discussion that &quot;Our study reveals that mCpG-dependent binding activity of KLF4 serves as the link between methylated CpG and changes in chromatin status&quot; is not supported by the data shown. It is &quot;a&quot; link, but not &quot;the&quot; link.</italic></p><p>We have changed this sentence to &quot;Our study reveals that mCpG-dependent binding activity of KLF4 <italic>serves</italic> as a link between methylated CpG and changes in chromatin status&quot; (Discussion section, paragraph five).</p></body></sub-article></article>